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SUMMARY 
Introduction 
Low-molecular-weight heparins (LMWHs) are modified heparin fractions with a 
molecular weight range of 2 OOO to 8 OOO Da prepared by chemical or enzymatic 
depolymerisation of unfractionated heparin (UFH). Although UFH was the standard 
anticoagulant, LMWHs constitute an effective alternative antithrombotic therapy to UFH, and 
they have more favourable pharmacokinetic profiles and several clinical advantages. LMWHs 
present a special set of difficulties for chemical and structural analysis because they are 
highly negatively charged, structurally complex, and polydisperse in nature. Various LMWHs 
are prepared by different processes and show dissimilarity in physical, chemical and 
biological properties. Lack of versatile and efficient analytical techniques makes 
characterisation and stability analysis of various LMWHs difficult. An earlier study of 
enoxaparin stabilities showed that the ant1factor (AFXa) activity decreased upon freezing and 
showed an unusual pattern of change upon heating. 
Objectives 
The main aim of the study was to investigate the mechanisms behind the observed 
activity changes of enoxaparin upon storage at elevated and reduced temperatures, with the 
potential goal of improving the stability of LMWHs. Secondary objectives were to develop new 
analytical techniques in order to accomplish the above mentioned aim. 
Analytical methods development 
A low-volume microtitre plate assay was developed for the determination of AFXa 
activity of enoxaparin. This method was validated against a standard method and equivalent 
results were obtained. A simple, selective and accurate capillary electrophoresis (CE) method 
was developed with a superior resolution than previously reported CE methods for the 
separation and identification of various LMWHs and UFH. The developed CE method was 
successfully applied to demonstrate batch-to-batch variations in enoxaparin. An efficient 
ion-interaction reversed-phase high performance liquid chromatography 
xii 
(ion-interaction RP-HPLC) method with diode array detection was developed. Resolution of 
various LMWHs was superior to any of the previously reported analytical techniques. A novel 
application of ion-interaction RP-HPLC coupled to an evaporative light scattering detection 
(ELSD) system was also developed. 
Freezing study 
Enoxaparin solutions were frozen and thawed under different conditions and the 
AFXa activity was determined. Freezing adversely affected the AFXa activity of enoxaparin 
solution. Physical investigations of enoxaparin solution suggested that formation of ice 
crystals or glassy state transitions were not responsible for the loss in activity. Chemical 
investigations of enoxaparin solution showed that the loss of AFXa activity did not involve the 
loss of N-sulfate groups or breakdown of glycosidic bonds. Freezing-induced loss of AFXa 
activity could be reduced by the inclusion of dimethyl sulfoxide (DMSO), by dilution with water 
and by controlling the freezing and thawing rates. The activity loss could be partially reversed 
by sonication and sonication was more effective in the presence of DMSO. The loss in AFXa 
activity was found by high performance size exclusion chromatography (HP-SEC) to be 
primarily due to aggregation. 
Dilution study 
Commercially prepared undiluted enoxaparin or enoxaparin diluted with sterile water 
or sterile 4% glucose was aseptically transferred into plastic syringes or glass vials. Samples 
were kept at 4 °C, -12 °C or -80 °C for up to 31 days. The AFXa activity of stored solutions 
was determined after 0, 7, 14 and 31 days. The AFXa activity of the diluted samples was 
compared with the AFXa activity of undiluted enoxaparin sodium solution stored for the same 
time periods at 4 °C. Enoxaparin sodium diluted with 4% glucose retained greater than 99% 
of its initial AFXa activity at 4 °C after 31 days. Enoxaparin sodium diluted with water lost 
almost 10% of its original activity after 31 days at 4 °C and lost more than 10% of its activity 
after freezing at -12 °C or -80 °C. Storage in glass or plastic containers made no difference to 
the loss in the activity. 
xiii 
Heating study 
Enoxaparin samples were kept at 70 °C for up to 576 hours. Enoxaparin activity 
decreased to 74% of its initial AFXa activity after 8 hours at 70 °C followed by a rapid 
increase in the activity after 12 hours to 94% and then a gradual decrease in the AFXa 
activity. The chemical changes to enoxaparin which account for the AFXa activity changes 
following thermal degradation were studied. Enoxaparin was heated at 70 °C for up to 
24 days in the presence and absence of various concentrations of oxygen. Samples were 
collected at regular time intervals and AFXa activity, free sulfate groups, free amino groups 
and reducing capacity were determined. Samples stressed at 0, 8 and 12 hours were 
fractionated by HP-SEC. The fractions were collected and analysed by ion-interaction 
RP-HPLC and for AFXa activity and sulfate concentration. Enoxaparin thermal degradation 
resulted in the loss of sulfation, particularly N-sulfate groups, and the breakdown of glycosidic 
linkages confirmed by reducing capacity assay and CE analysis. 
The initial decrease (at 8 hours) and subsequent increase (at 12 hours) of enoxaparin 
AFXa activity was found to be unrelated to oxygen content. No differences between the 
O hours and the 8 hours samples were observed by HP-SEC. Ion-interaction RP-HPLC 
analysis of 0 hours and 8 hours treated fractions (collected by HP-SEC) clearly showed 
changes in some of the 8 hours treated fractions. Ion-chromatography (IC) and AFXa activity 
analyses of the fractions showed loss of sulfate groups and a corresponding decrease in the 
AFXa activity. Only some of the fractions lost sulfate and AFXa activity. Other fractions 
appeared to be more resistant to thermally-induced desulfation and retained their AFXa 
activity. HP-SEC of the 12 hours treated sample showed the presence of extra peaks which 
were confirmed by ion-interaction RP-HPLC. The increased activity after 12 hours at 70 °C 
was found to be because of the fragmentation of large oligosaccharides to smaller 
ohgosaccharides, as confirmed by AFXa activity analysis and increased in the number of 
reducing ends. 
XIV 
Conclusion 
CE and ion-interaction RP-HPLC methods were developed and successfully applied 
to investigate the mechanisms involved behind the loss in AFXa activity of enoxaparin under 
various storage temperatures and conditions. The observed loss in AFXa activity was 
consistent with an aggregation hypothesis. Aggregation was reversible by sonication and 
sonication was more effective in the presence of DMSO. Controlling the freezing or thawing 
conditions, dilution with water or addition of a small percentage of DMSO ameliorated the loss 
of enoxaparin AFXa activity. Dilution of enoxaparin with 4% glucose offers a potential method 
for the preparation of stable paediatric diluted doses of enoxaparin. Chemical and AFXa 
activity analysis following the heating of enoxaparin at 70 °C clearly distinguished thermally 
stable fractions from the thermally labile. The generation of new active fragments was found 
after heating with higher AFXa activity. The thermally stable fractions of enoxaparin offer the 
potential for new LMWH formulations with greater stability and shelf life. 
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Chapter 1 
CHAPTERl 
General Introduction 
1.1 HEPARIN 
Heparin, a clinical anticoagulant, has been one of the most effective and widely 
used drugs of the 20th century [1]. Heparin was discovered in the year 1916, by Jay 
McLean working with William Howell, and first used clinically by Clarence Crafoord. 
Heparin was identified as an anionic polysaccharide containing uronic acid residues [1] 
(Figure 1.1). However, early studies showed that heparin also contains 0-sulphate ester 
and N-sulfated glucosamine residues. Heparin consists of a group of 
glycosaminoglycans (GAGs), which are produced in mast cells and consist of long 
chains of alternating saccharide residues of uronic acid and glucosamine [2]: Over the 
past two decades, the structure of the pentasaccharide sequence that binds to the 
antithrombin (AT) site resulting in anticoagulant activity, has been discovered. 
Together with structure elucidation of heparin has come an improved understanding of 
its conformation [3-5] and interaction with various proteins [6-8]. 
D1sulfated disacchande D1sulfated disacchande Tnsulfated d1saccharide 
Figure 1.1 The chemical structure of a portion of a heparin chain showing trisulfated and 
disulfated disaccharides. Heparin chains contain approximately 75% trisulfated and 25% 
disulfated disaccharides. 
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1.2 HEPARIN: STRUCTURE AND BIOLOGICAL ACTIVITES 
Heparin is prepared by extraction from animal tissues including porcine 
intestine, bovine lung and ovine intestine. Heparin, like other natural polysaccharides, 
contains a large number of chains having different molecular weights (is polydisperse) 
[9,10]. Heparin chains (with an average molecular weight of 12000 Da) are primarily 
N-sulfated but also contain on an average a single N-acetyl group per chain [l]. 
Heparin is composed of a trisulfated disaccharide repeating unit (Figure 1.1), but also 
contains a large number of disulfated disaccharide units [8,11,12]. These additional 
disaccharides units add complexity to the heparin structure and are important for AT 
binding, which is essential for heparin's anticoagulant activity. The key structural unit 
of heparin is a unique pentasaccharide sequence (Figure 1.2). This sequence consists of 
three D-glucosamine and two uronic acid residues. The central D-glucosamine 
R=HorS03 
~ 
0 
Figure 1.2 The pentasaccharide sequence of heparin, whose binding to AT is important for 
anticoagulant activity. 
residue contains a unique 3-0-sulfate moiety that is rare outside of this sequence. 
Sulfate groups on the D-glucosamines, encircled in the figure, are found to be critical 
for retaining high anticoagulant activity. Elimination of any one of them results in a 
dramatic reduction in the anticoagulant activity. Removal of the unique 3-0-sulfate 
group results in complete loss of the anticoagulant activity [14-16]. Not all heparin 
2 
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chains contain an AT pentasaccharide binding site. Only 20-50% of the pol ysaccharide 
chains in heparin contain the AT binding site [1]. Some high molecular weight chains 
contain more than a single AT binding site and hence show a high level of 
anticoagulant activity [13]. 
Heparin has a molecular weight ranging from 5 OOO to 40 OOO Dalton (Da) with 
an average of 10 OOO to 15 OOO [17]. Heparin's major biological activity is its 
anticoagulant activity. It is used to prevent clot formation in extracorporeal therapy, 
such as kidney dialysis or following surgery [18]. Heparin has a number of other 
biological activities associated with its ability to bind to a large number of important 
proteins. Heparin stimulates the release of lipoprotein lipase from the endothelium and 
activates it, which contributes to its anti-atherosclerotic activity by decreasing the 
concentration of atherogenic lipoproteins [19]. Heparin also decreases atherogenesis by 
inhibiting smooth muscle proliferation that follows damage to the endothelium [20]. 
Heparin is an antiviral agent having anti-human immunodeficiency virus activity [21]. 
Heparin has a role in the regulation of new blood vessel formation and this activity may 
give heparin a role in processes where new blood vessel growth occurs, including 
wound healing, tumour growth, ovulation and fetal development [22,23]. Heparin binds 
to many enzymes and other proteins activating, inhibiting or protecting their activities 
[22,24]. 
1.3 PREPARATION OF COMMERCIAL HEPARIN 
Preparation of pharmaceutical grade heparin has changed with time as the 
principle tissue source has changed from dog or beef liver to beef lung and finally to 
porcine intestine [25]. Commercial preparation of heparin mainly involves five basic 
3 
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steps: the preparation of tissue, extraction of heparin from tissue, recovery of raw 
heparin, purification of heparin, and recovery of purified heparin [25]. 
The preparation of tissue begins with the collection of the appropriate animal 
organ tissue. The second step involves hydrolysis by proteolytic enzyme at alkaline pH, 
followed by filtration or screening of digested tissue to remove any large particles, 
yielding a deeply coloured solution containing peptides and nucleic acids. After this, 
the proteolytic enzyme is inactivated by heating the filtrate at 90 °C for 15 minutes. 
Anion exchange resin is used to adsorb the heparin. After complete adsorption of 
heparin, the resin is washed and the adsorbed heparin is eluted by sodium chloride 
solution. The concentrated crude heparin is normally filtered, precipitated and vacuum 
dried. Purification of heparin is performed by dissolution of the crude heparin in 
purified water followed by filtration at low pH to remove residual proteins and 
oxidation at alkaline pH to decolorize and depyrogenate the material. Cation exchange 
chromatography and ethanol precipitation are performed to remove extraneous cations 
and to reduce levels of nucleotides respectively. Recovery of purified heparin is 
performed by precipitation. The final product is either vacuum dried or redissolved in 
purified water, foll<?wed by various filtration steps. 
1.4 PHARMACOKINETICS OF HEPARIN 
Absorption of heparin is poor after oral administration since the heparin 
polysaccharide chain is degraded in gastric acid. Heparin must therefore be 
administered intravenously or subcutaneously [26]. Heparin should not be given 
intramuscularly because of unpredictable absorption rates, local bleeding, irritation and 
danger of haematoma formation [27]. There is evidence that heparin administered by 
intermittent intravenous injection is associated with more bleeding than when it is 
4 
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administered by a continuous intravenous route. Following injection, heparin binds to 
endogenous plasma proteins, such as histidine-rich glycoprotein, polymeric vitronectin, 
platelet factor, fibronectin and von Willebrand factor. Due to binding with proteins, less 
heparin is available to interact with AT and the anticoagulant activity of the 
heparin is reduced [28]. When heparin is given in therapeutic doses, close laboratory 
monitoring of clotting time is required. Because of its highly acidic sulfate groups, 
heparin exists as the anion at physiologic pH and is usually administered as the sodium 
salt. Heparin is partially metabolised in the liver by heparinase to uroheparin, which has 
only slight antithrombin activity. Twenty to fifty percent is excreted unchanged. 
1.5 LOW MOLECULAR WEIGHT HEPARINS (LMWHs) 
LMWHs are known as salts of GAGs. They have a molecular weight of less 
than 8 OOO Da. The goal of pharmaceutical scientists, before any LMWHs had been 
approved for human use, was to develop a product that resembled the structure of 
heparin in all possible aspects except molecular weight and ratio of antifactor Xa 
(AFXa) to antifactor Ila (AFila) activity [29]. LMWHs are obtained by controlled 
enzymatic or chemical depolymerisation processes. LMWHs are mixtures and each 
possesses distinctive biological properties depending on the content and structure of its 
components. A LMWH is characterised by its average molecular weight and 
polydispersity. The distribution of individual chains found in the mixture and their 
sequence are also important. The character of each LMWH is mainly dependent on the 
tissue source of the parent heparin and the method and conditions employed for its 
preparation [29]. 
LMWHs have replaced unfractionated heparin clinically to a large extent 
because of their desirable pharmacokinetic properties and fewer side effects [28]. 
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LMWHs are mainly used in the treatment of venous embolism, deep vein thrombosis 
and unstable angina [30-36]. They are also indicated in the prophylaxis of general and 
orthopaedic surgery, acute spinal cord injury, multiple trauma and in patients with 
ischaemic stroke [37-40]. 
1.6 DIFFERENT l\IBTHODS FOR THE PREPARATION OF LMWHs 
Treatment of heparin under acidic and neutral conditions leads to formation of 
small desulfated products [ 41]. As heparin molecules are not large enough to be 
shear-sensitive, physical parameters such as agitation result in no structural alteration or 
damage. Oxidative instability of heparin is a well known phenomenon. Various 
antioxidants like sodium metabisulphite and metal chelators are added to heparin at 
various stages to enhance its stability [41]. These observations resulted in the use of 
oxidative methods for the preparation of LMWHs. 
The enzyme heparin lyase I (heparinase) acts on heparin through P-eliminative 
cleavage in a random endolytic manner [ 42,43]. This enzymatic reaction can be 
enhanced chemically by esterification of the carboxyl group of the uronic acid residue 
and treating the resulting heparin with base [ 44]. Thus, a possible second mechanism 
for the manufacturing of LMWHs is offered by enzymatic or chemical P-eliminative 
cleavage. 
1.6.1 Oxidative depolymerisation 
Oxygen-containing reagents like hydrogen peroxide or ionizing y-irradiation 
(Figure 1.3) are used to break down heparin oxidatively [ 45-47]. These oxidative 
methods generate oxygen radicals which then oxidise the oxygen sensitive saccharide 
residues within the heparin polymer. Heparin chains contain both reducing and 
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non-reducing ends among which the latter are inert to hydrogen peroxide except when 
treated in the presence of alkali or metal catalyst. Treatment with hydrogen peroxide or 
ionization with y-irradiation lead to the generation of hydroxyl radicals which will 
subsequently react with the sugar residues and degrade them to the 1-, 2- and 3-carbon 
fragments without modifying the residues on either side of the attack point. Of these 
two methods only hydrogen peroxide is used for the preparation of commercially 
available LMWHs for clinical use (Table 1.1). 
Table 1.1 LMWHs, their average molecular weight and method of preparation. Adapted from 
Linhardt and Gunny, 1999 [29]. 
LMWH Mean Molecular Weight (Da) Preparation Method 
Ardeparin sodium 6 OOO Oxidative depolymerisation with H20 2 
Certoparin sodium 5500 Deaminative cleavage with isoamyl nitrite 
Dalteparin sodium 6 OOO Deaminative cleavage with nitrous acid 
Enoxaparin sodium 4500 13-elim inative cleavage of tHe benzyl ester 
of heparin by alkaline treatment 
Nadroparin calcium 5 OOO Deaminative cleavage with nitrous acid 
Reviparin sodium 3 900 Deaminative cleavage with nitrous acid 
Tinzaparin sodium 4500 13-eliminative cleavage with heparinase 
1.6.2 Deaminative Cleavage 
Oxidative depolymerisation of heparin through deamination is also a possible 
way to prepare LMWHs (Figure 1.2). In these reactions, either nitrous acid or another 
nitrosating reagent such as isoamyl nitrate is used to make heparin N-nitrosated at the 
amino group of its N-sulfoglucosamine residues. The resulting N-nitrososulfamide is 
unstable, loses nitrogen and sulfate groups and generates a carbocation at C-2 of the 
saccharide residues. Subsequent ring contraction of this residue and hydrolysis of the 
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adjacent glycosidic bonds give a LMWH. Several LMWHs prepared through 
deaminative cleavage are currently used clinically (Table 1.1). 
R = H or so;, Y = COCHa or so; 
~F,~~~ 
oso; NHY ~ !J CH.OH 
CH,OR ~co; cH,oso; 
0 ~ 0 Q-OR OH OH OH 
0 0 0 
Oxidation (HO") / Deamma!Ne deg<adatwo 
oso; NHY OR m NHso;-
cH
2
oso;- ~co;-~cHp: ~Q-cH,o:o; 
OR ~~· OH OH 
0 0 0 0 
NHSO, OR NHY n oso; NHS03 
Chemical 13-elimination ~ Enzymatic 13-elimination 
co;~~cH,oR ~co; Q-cHpso; 0 0 0 0 
(/._ OH OH OH OH OH 
0 0 0 
OR NHY OR m NHso;-
co; CH,OR ~co; 0 Q-CH,o:o; 
OH OH OH 
0 0 0 
oso; NHY OR m NHso; 
~):\~~~'~ f! 15-~% ~ l: NHY ~~ NHSO;' 
Figure 1.3 Four different depolymerisation processes to prepare commercial LMWHs. The 
heparin chain in the centre 1s reduced in length (n>m) to produce a LMWH. Adapted from 
Linhardt and Gunny, 1999 [29]. 
1.6.3 {J-eliminative Cleavage 
~-Eliminative cleavage processes, either enzymatic or chemical, are used to 
prepare commercially available LMWHs (Table 1.1). Depolymerization of heparin by 
enzymatic cleavage is carried out using heparinase [48]. The extent of reaction is 
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monitored by the change in absorbance associated with the formation of unsaturated 
residues [ 43,49]. Inactivation of the enzyme halts the depolymerisation process. The 
chemical B-elimination process involves treatment of heparin directly with base or 
quaternary ammonium salt [50,51]. Under this treatment B-elimination takes place, 
leading to a LMWH which contains an unsaturated urinate residue at its non-reducing 
ends. Enoxaparin is prepared by chemical B-eliminative cleavage of the benzyl ester of 
heparin with alkaline treatment. 
1.7 STRUCTURAL DIFFERENCES BETWEEN AND WITIDN LMWHs 
A total of eight LMWHs are approved for clinical use worldwide as shown in 
Table 1.1. All are prepared through chemical or enzymatic depolymerisation and have 
average molecular weights between 3 OOO and 7 OOO Da [9,52]. LMWHs display 
similar physical, chemical and biological properties. A close examination, however, 
suggests structural differences between these LMWHs. The average molecular weights 
and dispersity of different LMWHs showed marked variability determined by 
polyacrylamide gel electrophoresis (PAGE) and high performance size exclusion 
chromatography (HP-SEC) [53]. PAGE analysis of different digested LMWHs has 
demonstrated a variation in the presence and distribution of oligosaccharide chains of 
defined degree of polymerisation. Disaccharide compositional analysis of various 
LMWHs by PAGE has also revealed significant differences in the degree of sulfation 
between different LMWHs. [11,53]. 
Detailed study of chemically or enzymatically digested LMWHs by NMR has 
shown enormous differences in their structures. Preparation of LMWHs by deaminative 
depolymerisation (dalteparin) results in an anhydromannitol residue at the reducing end 
as shown in Figure 1.3. Treatment of heparin with nitrous acid to produce LMWH 
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results in a tetrasaccharide, containing an unusual reducing end residue that was 
observed following oligosaccharide analysis [54]. LMWH prepared by oxidatively 
using hydrogen peroxide (ardeparin) contains a higher degree of sulfation compared to 
LMWHs prepared by other methods. P-eliminative cleavage of heparin by heparinase 
causes the formation of 2-0-sulfo unsaturated uronate residues at the non-reducing end 
of the LMWH (tinzaparin) [29]. Chemical P-elimination is less specific, yielding both 
unsulfated and 2-0-sulfo unsaturated residues at the reducing end (Fig. 1.3) [29]. An 
average 15-25% of polysaccharide chains of LMWH prepared by chemical 
P-eliminative cleavage (enoxaparin) contain 1,6-anhydro groups at the reducing end. 
Two LMWHs, dalteparin and nadroparin, are produced by nitrous acid 
treatment. Disaccharide and oligosaccharide compositional analysis showed that 
dalteparin and nadroparin are more similar compared to other LMWHs produced by 
different processes but less similar to each other than to different batches of the same 
respective LMWH from a single manufacturer [52,55-58]. Enoxaparin and tinzaparin, 
produced by chemical and enzymatic P-elimination respectively, are structurally related 
to each other (both having unsaturated uronate non-reducing ends) but have different 
physical and chemical properties [52,55-58]. LMWHs prepared by different processes 
are dissimilar in both their end-groups and physical and chemical properties. Studies 
have shown real and significant differences between and within various LMWHs based 
on their biological activity. The type of heparin chosen to be degraded and the degree 
of purification of the starting material both contribute to the final characteristics of the 
LMWH. 
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1.8 MECHANISM OF ACTION OF HEPARIN AND LMWHs 
Heparin exerts its anticoagulant activity by activating AT. A unique 
pentasaccharide sequence binds to AT and makes a conformational change within the 
AT structure that accelerates its interaction with thrombin and factor Xa by 1 OOO times. 
The major difference between LMWHs and unfractionated heparin is their relative 
inhibitory effect on factor Xa and thrombin [59]. Both LMWHs and unfractionated 
heparin can inhibit factor Xa, by binding to AT as shown in Figures 1.4 and 1.5. To 
inactivate thrombin, heparin must bind to AT and the enzyme, thereby forming a 
ternary (heparin-AT-thrombin) complex. Heparin chains are composed of more than 16 
saccharide units so they can easily form the ternary complex [60]. 
Figure 1.4 Mechanism of action of heparin. Adapted from Whiteand and Ginsberg, 2003 [60]. 
Unlike heparin, LMWH chains are composed of fewer than 16 saccharide units 
so they can not bind to both thrombin and AT to form the ternary complex and hence 
have an inhibitory effect only on factor Xa not on thrombin [60]. The way in which 
heparin and LMWHs exert an anticoagulant effect is not limited to just inhibition of 
factor Xa and factor Ila, there is also strong evidence that both increase the release of a 
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tissue factor pathway inhibitor from the endothelium, which reduces the level of blood 
coagulation factor. 
Figure 1.5 Mechanism action of LMWH. Adapted from Whiteand and Ginsberg, 2003 [60] . 
1.9 DETERMINATION OF THE ACTIVITY OF LMWHs 
LMWHs have a higher affinity for inhibition of clotting factor Xa compared to 
unfractionated heparin. For this reason antifactor (AFXa) assays are always used to 
measure LMWH activity [61]. The activity of heparin is usually estimated by different 
clotting tests such as Activated Partial Thromboplastin Time (APPT), Thrombin 
Clotting Time (TCT) or Activated Clotting Time (ACT). These assays are non-specific 
and reflect the ability of heparin to interfere with several coagulation cascades. Specific 
assays measure the heparin or LMWH accelerated AT activity on a single coagulation 
enzyme, either factor Xa or factor Ila. The enzyme activity is determined either by 
clotting assay or by chromogenic assay [61]. 
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1.9.1 Clotting AFXa assay 
In 1973, Yin and coworkers introduced a clotting AFXa assay [62]. It is based 
on the inhibitory activity of heparin or LMWHs on factor Xa. In the starting phase of 
the reaction, the amount of factor Xa neutralized is directly proportional to the heparin 
concentration, if AT is present in excess. Residual factor Xa is then measured using a 
clotting technique. This assay is not suitable for the measurement of plasma AFXa 
activity of LMWHs because of their sensitivity toward residual antifactor Ila (AFila) 
activity [63]. 
1.9.2 Chromogenic AFXa assay 
Teien and co-workers in 1976 introduced a photometric version of the AFXa 
clotting assay [64]. This method was further modified by addition of pure AT of known 
concentration to the sample, to reduce the influence of varying concentrations of AT. 
The principle of this modified method was the same as the clotting-based assay except 
that the AFXa activity was determined by using a synthetic chromogenic factor Xa 
substrate. In chromogenic AFXa activity determination a known amount of excess 
factor Xa and patient plasma are added along with excess AT. Factor Xa will be 
inhibited if heparin or LMWH is present in human plasma, based on the fact that 
heparin or LMWHs binds to AT. In the chromogenic assay peptide substrates are used. 
They are generally composed of 3-4 amino acids with para-nitroaniline (pNA) which is 
the chromogenic group attached to the carboxy terminal of arginine. When the synthetic 
substrate is cleaved by factor Xa, the yellow chromophore pNA is liberated. The colour 
is measured at 405 nm, either during the reaction (kinetic method) or after stopping the 
r 
reaction (endpoint method). The colour intensity is inversely proportional to the amount 
of LMWH or heparin present. Results are reported as anticoagulant concentration in 
AFXa units/ml, such that high AFXa values indicate high levels of anticoagulation and 
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low AFXa values indicate low levels of anticoagulation. Chromogenic assays using 
synthetic peptide-based substrates and purified factor Xa or factor Ila offer accurate and 
reliable measures of anticoagulant activity [63]. Chromogenic assays are not subject to 
many of the interferences observed in older clotting-based assays [63]. 
1.10 COMPARISON OF LMWHs AND UNFRACTIONATED HEPARIN 
Several studies have shown possible benefits of LMWHs over unfractionated 
heparin in clinical use. These advantages over heparin are justified by various desirable 
chemical and physical properties of LMWHs. Major drawbacks of heparin are its 
non-linear dose-dependent kinetics and the unpredictable effect of a standard dose [30]. 
Monitoring of clotting time is required for heparin. Laboratory monitoring with the 
LMWHs is not required because of their linear dose-dependent kinetics and they do not 
prolong the APTT. Affinity of LMWHs towards proteins, platelets, vascular matrix 
proteins, endothelial cells and macrophages is less compared with heparin because of 
their reduced chain length. Fewer side effects (i.e. heparin-induced thrombocytopenia, 
bleeding complications), higher AFXa activity and superior bioavailability make 
LMWHs the drug of choice over heparin for various indications [30,59,60]. 
1.11 ANALYSIS OF HEPARIN AND LMWHs 
Heparin and LMWHs in particular have been the subject of considerable recent 
research into their chemical, biological and therapeutic properties. The limitation in 
understanding the composition of intact LMWHs or unfractionated heparin is the lack 
of high resolution analytical techniques. Heparin and LMWHs are linear 
polysaccharides, and have proven to be extremely difficult to analyse because of their 
high negative charge, structural complexity and high polydispersity [65-67]. These 
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characteristics make their separation, without further fractionation or depolymerisation 
prior to analysis, one of the most difficult analytical challenges. 
One approach is to chemically or enzymatically digest intact heparin or 
LMWHs with subsequent analysis by various analytical techniques. Ion exchange 
chromatography, following sample digestion, can be accurately used to determine the 
level of sulfation or the presence of contaminating metals or anions. PAGE has been 
successfully used to determine molecular weight and polydispersity of digested heparin 
and LMWHs [68]. In recent years capillary electrophoresis (CB) has gained popularity, 
making disaccharide and oligosaccharide analysis extremely rapid and sensitive 
[54,69]. Strong anion exchange chromatography (SAX) has been the preferred 
analytical technique for the separation of depolymerised or fractionated heparin 
[70,71]. However, this method is limited by long retention times, poor separation and 
resolution of highly charged oligosaccharides, the inability to separate oligosaccharides 
containing hydrophobic protecting groups and the requirement for extensive desalting 
of digested oligosaccharides prior to analysis. A few applications of CB for the 
separation of intact LMWHs have been documented [72-7 4]. However, these 
techniques resulted in limited resolution of individual constituents of intact LMWHs. 
HP-SEC is the standard method for chromatographic analysis of intact LMWHs [10,74-
76]. It involves the time consuming production of essential molecular weight standards. 
HP-SEC gives an indication of the molecular weight profiles of LMWHs and can 
resolve the lower mass polymers, but fails to resolve higher mass components well 
[77]. Although HP-SEC resolves shorter molecules, it can not distinguish between 
different oligosaccharides of the same or similar mass. This requires the collection of 
fractions from HP-SEC, and their analysis by a second method. This is a time 
consuming and laborious process. 
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It is established that LMWHs are structurally different depending on the 
employed method of depolymerisation or fractionation. Structural differences between 
various LMWHs may differentiate them by their chemical profiles or their 
pharmacokinetic/pharmacodynamics properties. As a result, each of these LMWHs 
should be identified as a separate entity. Identification of physicochemical properties of 
each LMWH is necessary. Particular consideration is required for the development of 
simple analytical methodology, capable of detecting differences between two different 
LMWHs or two different batches of the same LMWH without the requirement for 
depolymerisation before analysis. 
LMWHs are commanding more and more attention in pharmaceutical and 
clinical fields. Each LMWH is a complex mixture of various structurally different 
oligosaccharides and may have different chemical or physical stability. Studies of these 
intact LMWHs under different storage conditions would potentially provide important 
information about their stability and the mechanism(s) responsible for their 
degradation. Accelerated decomposition study of intact LMWHs under different 
conditions, the stability of different oligosaccharides, analysis of degradation product(s) 
and investigation of possible mechanism(s) of degradation have not been described, 
despite the routine clinical use of LMWHs. 
An earlier study of enoxaparin stability in our laboratory showed that the AFXa 
activity decreased upon freezing and showed an unusual pattern of change upon 
heating. The primary objective of this study was to investigate the mechanisms behind 
the observed activity changes of enoxaparin upon storage at elevated and reduced 
temperatures, with the potential goal of improving the stability of LMWHs. New 
analytical techniques including CE and ion-interaction RP-HPLC were developed and 
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validated for the characterisation and stability analysis of various LMWHs in order to 
accomplish this objective. 
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CHAPTER2 
Development of a Modified Low Volume Microtitre Plate Assay 
Method for the Determination of AFXa Activity of Enoxaparin 
2.1 SUMMARY 
The aim of this study was to develop and validate a modified low-volume microtitre 
plate assay for the determination of the AFXa activity of enoxaparin solution. The standard 
ACTICHROME® kit procedure for the AFXa activity determination of LMWHs was modified. 
This modified assay was validated in terms of linearity, inter- and intra-day accuracy and 
precision. This methodology is more sensitive than the standard kit method, allowing AFXa 
activity measurement of enoxaparin with much lower concentrations. This method is more 
economical as it uses smaller quantities (1/81h) of reagents and samples. Unlike the standard 
kit method, this modified method allows simultaneous determinations and reduces the time 
required per sample analysis. This method is accurate and reproducible for routine AFXa 
activity determination of enoxaparin. 
2.2 INTRODUCTION 
The anticoagulant activity or potency of heparin or LMWH is expressed in 
terms of international units (IU)/ml. An IU is defined as the amount of heparin or 
LMWH that is required to prevent the coagulation of 1 ml of whole blood for 3 
minutes. There are number of different types of assays to measure anticoagulant 
activity of UFH or LMWH. One measure of the anticoagulant activity is determined 
by the ability to inhibit factor Xa in the presence of AT. At present, the chromogenic 
AFXa assay is considered the gold standard method to determine AFXa activity of 
LMWHs as it is not subject to many of the interferences observed in older clotting 
assays [61]. ACTICHROME® is one of the commercially available chromogenic 
assay kits. It provides human AT III (lyophilized human AT III in buffer of 0.05 M 
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Tris-HCl, 0.175 M NaCl, 7.5 mM EDTA, pH 8.4), lyophilized bovine factor Xa 
(20 nKat) and lyophilized FXa substrate (4 µmoles). As shown in Figure 2.1, for the 
AFXa activity analysis of sample, AT III is added to the sample to form a heparin-AT 
III complex. The sample is then incubated with a known amount of factor Xa, and a 
chromogenic substrate specific for factor Xa, is added. At this stage two simultaneous 
reactions occur. The sample and AT III complex inhibits factor Xa and, secondly, 
factor Xa hydrolyses the chromogenic substrate. Hydrolysed substrate is yellow in 
colour and the intensity of the colour is measured by spectroscopic analysis at 405 
nm. 
AT-Ill 
LMWH 
1. Complex inhibits FXa 
2. FXa hydrolyses the 
Chromogenic substrate 
l 
Yellow colour 
LMWH - AT-Ill Complex 
Chromogenic 
substrate 
Known amount of 
Factor Xa 
LMWH-AT-111 Complex 
+ 
Factor Xa 
Figure 2.1 Schematic presentation of chromogenic assay to measure the AFXa activity of 
LMWHs. 
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There are several problems associated with the commercially available 
ACTICHROME® AFXa assay kit. It is technically difficult to perform manually as a 
change in the incubation temperature (between 1 °C and 3 °C), time, and volume of 
added reagents have affect on the binding of sample to AT III and subsequent 
inhibition of factor Xa. Simultaneous analysis of samples is not possible with this 
AFXa assay kit method. It is expensive and in total only 80 samples can be analysed 
from the provided reagent in a single prepacked kit. Therefore there is an important 
need to have a simple and economical chromogenic assay which allows the 
simultaneous determination of AFXa activity, requires less volume of reagents for 
sample analysis, and hence decreases the technical complexity and cost per sample 
analysis. The LMWH enoxaparin was selected as a test analyte to develop a modified 
low-volume mictotitre plate assay. The assay was validated in terms of linearity, 
reproducibility, inter- and intra-day accuracy and precision. 
The objective of this study was to develop and validate a simple, faster, 
economical and sensitive modified low-volume mictotitre plate assay for the analysis 
of AFXa activity of LMWHs. 
2.3 EXPERIMENTAL 
2.3.1 Materials 
The sodium salt of enoxaparin (10 OOO IU/ml) was purchased from Aventis 
Pharma Pty Ltd. (Sydney, NSW, Australia) and used as supplied at pH 7.0. The AFXa 
activity kit# 832 (ACTICHROME®) was from American Diagnostica (Stamford, CT, 
USA). Microtitre plates were flat-bottomed polystyrene plates from Coming 
(Coming, NY, USA). Polyethylene capped 1.4 ml centrifuge vials were from 
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Eppendorf (North Ryde, NSW, Australia). All spectrophotometric measurements 
were made with a Bio-Rad microplate reader Model-680 (Bio-Rad Laboratories, 
Hercules, CA, USA). Acetic acid and sodium chloride were of analytical grade from 
Sigma Aldrich (Castle Hill, NSW, Australia). The multi block heater was from 
Rankin Biomedical Corporation (Clarkston, MI, USA). 
2.3.2 Analysis of AFXa Activity 
The activity of enoxaparin was determined using the AFXa chromogenic assay 
kit to measure its potentiating effect on AT III inhibition of activated factor Xa. The 
use of low volume microtitre plates allowed a micro-method to be developed. 
Enoxaparin solution (5 µl, 10 OOO IU/ml) was pipetted into 2 ml capped polyethylene 
tubes and diluted to 1 OOO µl with 995 µl of saline (0.9% w/v sodium chloride) to 
obtain a solution with 50 IU/ml activity. A sample (10 µl) of the 50 IU/ml enoxaparin 
solution was diluted to 1 OOO µl with 990 µl of saline to obtain a solution with 
0.5 IU/ml concentration. The 0.5 IU/ml solution (250 µl) was serially diluted with 
equal volumes of saline to obtain 0.25, 0.125, 0.625 and 0.0325 IU/ml concentrations. 
The reagents provided in the kit were diluted to 5 ml with deionised water according 
to the manufacturer's instructions. Two modifications were made from the standard 
procedure: 25 µl of each reagent and 10 µl of sample were used instead of 200 µl and 
25 µl respectively, and the incubation time was extended to 10 minutes instead 5 
minutes after addition of spectrozyme FXa substrate. Up to 35 samples (10 µl each) 
were transferred into capped polyethylene tubes and heated to 37 °C in an aluminum 
block heater with water placed in each heating compartment to maximise heat 
transfer. Each provided reagent was sequentially added to tubes using same multi 
dispensing pipetter at 1 second intervals to minimise the pipetting error and to 
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maintain identical incubation time for each sample. AT III (25 µl) was added first to 
the each sample. After 120 ± 2 seconds factor Xa (25 µl) was identically added and 
incubated for 60 ± 2 seconds. Substrate FXa was then added and each solution was 
mixed and incubated for 10 minutes. Stop reagent (25 µl glacial acetic acid) was then 
added to each tube. Vials were centrifuged at 15 OOO rpm for 1 minute and contents 
were carefully transferred to wells of a microplate using micropipetter. The intensity 
of the colour, which was inversely proportional to the concentration of enoxaparin 
present in the sample, was read at 405 nm using a microplate reader, after shaking for 
60 seconds to remove any air bubbles present. Each sample was analyzed for AFXa 
activity in triplicate. 
2.3.3 Linearity 
Enoxaparin solution (10 OOO IU/ml) was diluted with normal saline solution to 
obtain 5 different concentrations (0, 0.0312, 0.0625, 0.125 and 0.25 IU/ml). These 
standards were analysed for AFXa activity using the low-volume micrtotitre plate 
method. Three independent calibration plots were constructed and fit to a linear model 
by least-squares regression. 
2.3.4 Reproducibility 
Reproducibility was determined by repeat analysis of 7 enoxaparin samples 
having the same concentration (0.0625 IU/ml) and AFXa activity was determined. 
Reproducibility results are expressed as% relative standard deviation(% RSD). 
2.3.5 Precision 
Intra-day precision was evaluated by AFXa determination of 5 different 
concentrations of enoxaparin solution (n=5) on the same day, under the same 
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experimental procedure and controlled conditions. The inter-day precision of the 
method was determined by AFXa analysis of 5 different concentrations of enoxaparin 
solution over four consecutive days (n=5). Results obtained by the modified 
microtiter plate method were compared with the standard methods using the assay 
performance measures provided with the kit instruction leaflet. 
2.3.6 Accuracy 
futra- and inter-day (over four consecutive days) accuracy of the micro titre 
plate method were investigated with the repeat analysis of 5 different concentrations 
of enoxaparin solution (n=5). Mean intra- and inter-day accuracy was calculated as 
follows: (observed reading-actual reading)/ actual reading x 100. Results are presented 
as% RSD. 
2.4 RESULTS AND DISCUSSION 
Three independent calibration plots were generated by plotting the 5 different 
concentrations of enoxaparin solution versus absorbance as shown in Figure 2.2. 
Good linearity was obtained in the 0.0325-0.25 IU/ml range compared to the 0.2-0.8 
IU/ml range (standard kit method) for the determination of AFXa activity of 
enoxaparin solution. This result has demonstrated that this method gives linear 
absorbance response with a low concentration range of enoxaparin and hence is more 
sensitive than the standard kit method. A linear regression equation was calculated by 
the least squares method, and the values of the correlation coefficient was found to be 
r2~0.9884 for the newly developed low volume microtitre plate method compared to 
r2=0.953 for the standard kit method (degree of freedom is 5 for each of the compared 
system). 
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The reproducibility of the method was determined by assaying samples of 
enoxaparin with the same concentration (n=7) and results are shown in Table 2.1. The 
enoxaparin activity ranged from 1.02 x 104 to 1.18 x 104 IU/ml, with an average value 
of 1.07 x 104 IU/ml and an RSD of 3.16%. 
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Figure 2.2 Calibration plots of the low-volume microtitre plate method for determination of 
AFXa activity showing absorbance (mean ± 95%confidence interval) at 405 nm vs. AFXa 
activity of standard enoxaparin solutions, (n=5). 
Table 2.1 Reproducibility of the microtitre plate assay obtained for the determination of AFXa 
activity of enoxaparin sodium (0.0625 IU/ml, n=7). 
Sample assay AFXa activity (I U/m I) Average AFXa activity (IU/ml) %RSD 
1 0.061 
2 0.063 
3 0.067 
4 0.066 0.064 4.14 
5 0.061 
6 0.060 
7 0.064 
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Intra- and inter-day accuracy and precision of the newly developed 
low-volume microtitre plate method were determined and results are presented in 
Table 2.2 together with the standard kit method results given by the manufacturers. 
Percentage RSD values obtained for both accuracy and precision were less than 5%. 
The microplate method developed here demonstrated low intra- and inter-assay 
variation, suggesting accuracy and precision comparable with the standard kit method. 
Table 2.2 Assay performance of the microtitre plate method for determination of AFXa activity 
and comparison with the standard kit method, (n=5). 
Enoxaparin Intra-day Intra-day Inter-day Inter-day 
(Units/ml) precision accuracy precision accuracy 
(%RSD) (%RSD) (%RSD) (%RSD) 
Microtitre 
method 0.00 1.5 1.06 2.9 0.56 
0.0325 1.4 -12.1 3.2 -1.9 
0.0650 2.9 4.8 3.6 4.7 
0.125 1.1 - 9.1 3.9 -5.6 
0.250 2.7 - 2.1 4.6 -2.5 
Standard kit 0.24 2.9* not available 6.2* not available 
0.48 5.1* not available 9.3* not available 
*results provided by the kit manufacturer 
2.5 CONCLUSION 
Extensive dilution of enoxaparin (in the order of 105) in the microtiter plate 
assay gives scope for the measurement of lower concentrations of enoxaparin or its 
constituents (0.0325 to 0.25 IU/ml) with appropriately adjusted dilution level 
compared to the standard kit method (0.2 to 0.8 IU/ml). AFXa activities analysed by 
chromogenic AFXa assay using the microtitre plate method developed here 
demonstrated low intra- and inter-assay accuracy and precision. The microplate 
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method allows the use of smaller quantities of reagents and samples. For analysis of 
each sample, the volume of sample and reagent is reduced by 1/5th and 1/8th and hence 
the cost also decreases. As many as 35 determinations could be performed 
simultaneously which decreases the time required for the assay compared with the 
standard method. This method is sensitive and possesses good linearity, precision and 
accuracy. The results of validation show that the developed modified low-volume 
microtitre plate method is accurate and can be applied to the routine AFXa activity 
determination of enoxaparin solution. 
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CHAPTER3 
A Simple Capillary Electrophoresis Method for the Rapid 
Separation and Determination of Intact Low-Molecular-Weight 
and U nfractionated Heparins 
3.1 SUMMARY 
A simple, selective and accurate CE method has been developed for the rapid 
separation and identification of various LMWHs and heparin. The developed method used a 
70 cm fused silica capillary (50 µm i.d.) with a detection window 8.5 cm from the distal end. -
' 
Phosphate electrolyte (pH 3.5; 50 mM), an applied voltage of -30 kV, UV detection at 230 nm 
and sample injection at 20 mbar for 5 seconds were used. The method was successfully 
applied to the European Pharmacopeia LMWH standard (EP-LMWHS), dalteparin, 
enoxaparin and heparin with a significant reduction in the run time and increased resolution 
compared with previously reported CE methods. Different CE separation profiles were 
obtained for various LMWHs and heparin showing significant structural diversity. The current 
methodology was sensitive enough to reveal minor constituent differences between two 
different batches of enoxaparin. This CE method also clearly showed chemical changes that 
occurred to LMWHs under different stress conditions. The sensitivity, selectivity and simplicity 
of the developed method allows its application in research or manufacturing for the 
identification, stability analysis, characterisation and monitoring of batch-to-batch consistency 
of different LMWHs and heparin. 
3.2 INTRODUCTION 
Over the past two decades, CE has been increasingly applied as a sensitive 
method of high resolving power for the analysis of complex mixtures of peptides, 
nucleotides and polysaccharides [78,79]. However, most of the polysaccharide work 
utilising CE involves the analysis of chemically or enzymatically depolymerised 
oligosaccharides [54,74,78-88]. Only a few applications of CE for the analysis of 
intact anionic polysaccharides have been documented [72,73,89-93]. Malsch et al 
[72], Ramasamy et al [73] and Toida et al [74] provide examples of the potential use 
of CE for the analysis of intact LMWHs, however these CE assays have limitations 
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associated with resolution and run time. Ramasamy et al. [73] used an acidic copper 
sulfate buffer for the separation of LMWHs that resulted in a peak with a base width 
of nearly 30 minutes. Malsch et al. [72] used an acidic phosphate buffer for the 
analysis of heparin that resulted in a peak width of nearly 5 minutes. Similarly the 
acidic buffer containing copper employed by Toida and Linhardt [74] for heparin 
analysis resulted in a peak width of about 8 minutes. 
Polyanions can be separated by CE with either high or low pH buffers, using 
normal or reverse polarity [54,72]. GAGs are negatively charged over a wide range of 
pH values and hence possess a favourable electrophoretic mobility for CE, due to the 
large number of sulfate groups. Under acidic conditions electroosmotic flow (EOF) is 
almost negligible due to protonation of silanol groups on the fused silica capillary 
surface. Samples introduced from the cathodic end migrate towards the anode without 
influence from the EOF. The separation of LMWHs is directly proportional to the 
average number of sulfate groups present in the repeating units [86]. In an alkaline 
environment the intrinsic mobility of the EOF is high due to dissociated silanol 
groups. Samples introduced from the anode possessing lower electrophoretic mobility 
than the EOF are swept towards the cathode [85,94,95]. 
Up to the present time CE has been under-exploited for polysaccharide 
analysis. An extensive literature review failed to find a versatile method with high 
resolution and a short run time for the separation of intact LMWHs, for the evaluation 
of stability and batch-to-batch variation in pharmaceuticals. Particular attention must 
be paid to the efficj.ency, precision, accuracy and selectivity of any analytical method 
used for pharmaceutical quality control. The LMWH dalteparin was selected as a test 
analyte to develop a simple and rapid CE separation method. Several parameters were 
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investigated such as buffer concentration, pH of the background electrolyte, different 
capillary lengths and diameters and the amount injected. The developed CE method 
was validated in terms of linearity, precision, accuracy and selectivity. Furthermore, 
the developed CE method was applied to the characterisation of structurally different 
LMWHs and different batches of the same LMWH, and chemically and thermally 
stressed enoxaparin and dalteparin to demonstrate its potential in applications for the 
analysis of intact LMWHs. 
The objectives of this study were to develop and validate a simple and 
versatile CE method to separate and identify different LMWHs and heparin without 
depolymerisation or fractionation prior to analysis, to detect structural or chemical 
changes in LMWHs at different storage temperatures and conditions, and to evaluate 
batch-to-batch consistency of the same LMWH. 
3.3 EXPERIMENTAL 
3.3.1 Alaterials 
The sodium salts of dalteparin (12 500 IU/ml) and heparin were purchased 
from Pharmacia (Rydalmere, NSW, Australia). The sodium salt of enoxaparin 
(10 OOO IU/ml) was purchased from Aventis Pharma (Sydney, NSW, Australia). The 
European Pharmacopeia low-molecular weight heparin standard (EP-LMWHS) was 
from Pharmacopee Europeenne (Strasbourg, France). Orthophosphoric acid, sodium 
hydroxide, sodium chloride, hydrochloric acid and hydrogen peroxide were of 
analytical grade and purchased from Sigma Aldrich (Castle Hill, NSW, Australia). 
Electrolytes and standard solutions were prepared from Milli-Q water and were 
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filtered through a 0.22 µm pore size membrane filter (Millipore, NSW, Australia) 
prior to use. 
3.3.2 Instrumentation 
An Agilent3D capillary electrophoresis instrument (Waldronn, Germany), 
equipped with a deuterium UV lamp and diode array detector (190-600 nm) was used 
for CE investigations. Data acquisition and instrument control were carried out using 
Agilent Chemstation system software. Bare fused silica capillaries were purchased 
from Polymicro Technologies (Phoenix, AZ, USA). A detection window was 
established through the polyimide coating at 8.5 cm from the capillary end using a 
butane torch. The detection wavelength and separation temperature were 230 nm and 
25 °C respectively. PL-600 Lab pH Meter (MRC Limited, Holon, Israel) was used to 
determine the pH of the sample solution. Calibration with at least two different buffer 
standards was performed every time the pH meter was used. The first calibration 
standard used with a pH of 7 .00 (neutral pH), and the second standard was selected to 
match the pH range in which the measurements were to be taken. The pH 
measurements of the calibration solutions and the samples were carried out at 25 °C. 
3.3.3 CE analysis 
Between each run, the capillary was flushed for 1 minute with electrolyte. The 
samples were introduced into the cathodic end of the capillary by hydrodynamic 
injection for 5 seconds at 20 mbar. The separation was performed in reverse polarity 
mode with a constant voltage of -30 kV. In order to ensure reproducible results of the 
CE method, the capillary was conditioned by applying a voltage of -30 kV with the 
electrolyte solution for 20 minutes at the start of each day. The capillary was flushed 
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with Milli-Q water for 5 minutes followed by electrolyte for 2 minutes prior to 
running samples. 
3.3.4 Electrolyte preparation 
A stock solution of phosphate electrolyte (200 mM) was prepared from 
phosphoric acid with a minimal concentration of 85% w/v. The pH was adjusted to 
2.0 by careful addition of 1 M sodium hydroxide solution. Preparation of phosphate 
electrolytes of different concentrations and pH values was performed by appropriate 
dilution of electrolyte stock solution with Milli-Q water and adjustment of pH using 1 
M sodium hydroxide solution. 
3.3.5 Method development 
The method development was performed using dalteparin solution diluted 
with Milli-Q water to a concentration of 5 mg/ml. Fused silica capillaries of 30, 50 or 
70 cm length with 50 or 75 µm i.d. were used. Phosphate electrolyte (20, 50 or 
100 mM) with a pH of 2.0, 3.5 or 5.0 was prepared from the stock solution. Analyses 
were run with an applied voltage of -10, -20 or -30 kV. The effect of salt on the 
separation parameters was determined using dalteparin (40 mg/ml) prepared with or 
without 20 mM sodium chloride. 
3.3.6 Assay performance 
Intra- and inter-day (over five consecutive days) precision were investigated 
using peak area, with repeat analysis (n=6) of 5 mg/ml dalteparin solution. The 
intra-day precision of different concentrations of dalteparin (10, 20 and 40 mg/ml, 
n=6) was also determined. Mean intra- and inter-day accuracy were calculated as 
follows; (observed concentration- expected concentration)/expected concentration 
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xlOO. The linearity of the method was investigated using 2.5, 5, 10, 20 and 40 mg/ml 
dalteparin (estimated using correlation coefficient r2) and peak retention time were 
obtained on each of the 5 days. 
3.3. 7 Degradation of dalteparin 
Dalteparin and enoxaparin solutions were subjected to chemical and thermal 
stresses in sealed N2-filled glass ampoules, but the solutions were not degassed. 
Dalteparin solutions (100 mg/ml) were mixed with either 0.5 M hydrochloric acid or 
concentrated hydrogen peroxide and then heated at 100 °C for 30 minutes. 
Enoxaparin solution (100 mg/ml) was mixed with concentrated hydrogen peroxide 
and then heated at 100 °C for 30 minutes. A further sample of enoxaparin (100 
mg/ml) was heated at 70 °C for 2 hours. CB analyses were performed on both stressed 
and unstressed samples for comparative purposes. 
3.3.8 Preparation of heparin and various LMWHs samples 
Heparin (5 OOO IU/ml), EP-LMWHS, enoxaparin (10 OOO IU/ml) and 
dalteparin (12 500 IU/ml) were diluted to 10 mg/ml with Milli-Q water before CB 
analysis. Six samples were analysed in all cases to test the reproducibility of the 
technique. 
3.4 RESULTS AND DISCUSSION 
3.4.1 Influence of separation parameters on dalteparin analysis 
Dalteparin was selected as the test analyte because it gave a simple peak in its 
electropherogram, and its CB analysis has been demonstrated previously [73]. Efforts 
were made to improve the electrophoretic separation of intact dalteparin. Molecular 
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dispersion of polysaccharides is known to be influenced by the applied voltage and 
the distance they are required to migrate before the detection window [96]. The 
highest voltage tested, -30 kV, gave rapid migration with acceptable peak shape. 
Consequently, this voltage was chosen for further analyses. The effect of different 
length and inner diameter combinations of the fused silica capillary were investigated 
with respect to the separation efficiency that could be achieved. When using the 
75 µm i.d. and 40 cm capillary, electrophoretic current was too high and current 
breakdown was observed, which had a negative impact on the separation. Decreasing 
the diameter of the capillary, increasing the length of the capillary or decreasing the 
ionic strength of the electrolyte has been shown to decrease the magnitude of the 
current generated [96]. This avoids the deleterious effects caused by boiling within 
the capillary. Increasing the length of the 75 µm i.d. capillary to 50 cm did not 
achieve better peak shape in the sample. Hence a 50 µm i.d. capillary was utilised 
which allowed relatively higher ionic strength electrolyte solutions to be used. This 
aided in sample stacking, hence improving sensitivity and reduced the magnitude of 
current generation compared to using the same higher electrolyte concentration in a 
75 µm i.d. capillary. Hence the best separation conditions achieved were obtained 
using a capillary of reduced i.d. (50 µm) of greater length (70 cm) with the 50 mM 
phosphate electrolyte at pH 3.5. 
3.4.2 Effect of electrolyte pH on the separation efficiency 
It is established that at low pH oligosaccharides can be efficiently separated 
without complexation with borate. Operation at lower pH ensures that the cathodic 
EOF is negligible all?wing migration of the analytes in the opposite direction towards 
the cathode. In order to maximise the electrophoretic mobility of the negatively 
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charged polysaccharide dalteparin, only acidic phosphate electrolytes (pH range 2 to 
5) were investigated. The strength of the electrolyte was maintained at 50 mM at all 
the tested pH values. 
The electrolyte pH was found to greatly influence the CE separation. 
Migration times varied across the tested pH range, with an increasing trend with 
increase in pH. As seen in Figure 3.1, at pH 5.0 a broad peak was 
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Figure 3.1 Effect of the electrolyte pH on the peak shape and migration time of the dalteparin 
peak (5 mg/ml): fused silica capillary of total length of 70 cm with 50 µm i.d; background 
electrolyte 50 m M phosphate buff er at pH specified; applied voltage of -30 kV; detection at 
230 nm, injection at 20 mbar for 5 seconds. 
obtained with longer migration time. This is because an increase in pH increases the 
EOF, whose direction is towards the inlet electrode. Consequently, the decreased net 
mobility of the solutes tends to increase the migration time, leading to higher 
dispersion of the solute in the capillary. At pH 2.0, the sample migrated earlier past 
the detector but with a poor peak shape. The peak height and area were also less at 
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pH 2.0 compared with results obtained using electrolyte of higher pH values. This 
could be explained by the partial degradation of dalteparin in very acidic conditions 
[97]. The best efficiency for dalteparin separation was achieved at pH 3.5. However, 
the electrolyte required replacement with freshly titrated electrolyte after every 
100 minutes due to the minimal buffering capacity of phosphate at this pH value. This 
time interval allowed the running of 10 sample analyses without any observed change 
in electrophoretic separation. 
3.4.3 Influence of the electrolyte concentration 
The effect of increasing the electrolyte strength from 20-200 mM was 
investigated, since increasing the electrolyte strength increases beneficial sample 
stacking, which improves separation efficiency. Increasing the concentration of 
electrolyte also increases the current during electrophoresis. Potential Joule heating 
effects limit the electrolyte concentration used. 
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Figure 3.2 Effect of the electrolyte concentration on the peak shape of dalteparin peak 
(5 mg/ml). CE conditions are the same as those described in Figure 3.1 at pH 3.5. 
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As shown in Figure 3.2, at a concentration of 100 mM phosphate electrolyte 
the peak became broad with tailing and at 200 mM the dalteparin peak shape 
degraded dramatically. The 50 mM electrolyte gave a sharp, well resolved and 
represented peak with a good compromise between current and peak shape. Highly 
negatively charged large molecules, including polysaccharides such as heparins, tend 
to become more compact in higher strength solutions due to charge neutralisation that 
effectively decreases the intra-molecular repulsive forces from the negatively charged 
sulfate groups. This change in conformation also benefits electrophoretic separation, 
as has been observed in the CE separation of highly sulfated carrageenans [98]. 
3.4.4 Effect of sodium chloride on the separation of dalteparin 
The presence of salt increases the viscosity and changes the ionic strength, 
hence the reproducibility of the method may be affected when analysing samples of 
varying salt concentrations. The presence of sodium chloride can have a strong effect 
on the stacking phenomenon and hence efficiency of the separation. The influence of 
sodium chloride on the separation of daltepar:in is illustrated in Figure 3 .3. It is 
apparent that the tested concentration of sodium chloride had virtually no effect on the 
CE performance and separation of dalteparin. The increase in the migration time with 
an increase in salt concentration was possibly because of decrease electrical field and 
simultaneously increased conductivity in the sample zone. However, the disturbance 
in the electrical field was minor because the sample volume injected was very small. 
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Figure 3.3 Electropherograms of dalteparin (40 mg/ml) diluted with 200 mM sodium chloride 
or Milli-Q water. CE conditions are the same as those described in Figure 3.2. 
3.4.5 Assay Performance 
Electropherograms of different concentrations of dalteparin are shown in 
Figure 3.4. The intra- and inter-day precision RSD was 3.2% (n=6) and 4.4% (n=5) 
respectively at the level of 5 mg/ml dalteparin. The intra- and inter-day accuracy was 
+4.0% and +5.5% respectively at 5 mg/ml dalteparin. The intra-day precision RSD at 
the level of 10, 20 and 50 mg/ml of dalteparin (n=6) was 3.8%, 4.4% and 2.3% 
respectively. Linearity estimated by correlation coefficient r2 was greater than 0.997 
for standard plots utilising 5 different concentrations of dalteparin (2.5, 5, 10, 20 and 
50 mg/ml) over 5 days. Mean migration time of dalteparin was 5.69 minutes with an 
intra-day and inter-day migration time RSD of 0.57% (n=6) and 1.99% (n=24) 
respectively. 
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Figure 3.4 Electropherograms of dalteparin 40 mg/ml (A), 20 mg/ml (B), 10 mg/ml (C) and 
5 mg/ml (D). CE conditions are the same as described in Figure 3.2. 
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3.4.6 Analysis of stressed IMWHs 
The CE profiles of degraded and non-degraded dalteparin using the method 
developed in this work, are presented in Figure 3.5. In the electropherogram of unstressed 
dalteparin (Figure 3.5), the main peak migrated at 6.42 minutes. The area of the main 
peak was reduced by more than 80% after acid stress. Two small peaks with migration 
times of 6.48 and 6.68 minutes were obtained, instead of a single main dalteparin peak, 
after treatment with H202. With acid stressed dalteparin, a degradation product migrated 
past the detector after 3.2 minutes. The peak of the degradation product was increased in 
height and area following peroxide treatment. 
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Figure 3.5 Electropherograms of dalteparin (5 mg/ml) before and after stressing under 
oxidative or acidic conditions. CE conditions are the same as those described for Figure 3.2. 
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Figure 3.6 Electropherograms of enoxaparin before and after stressing at 70 °C for 2 hours or 
under acidic conditions (B). CE conditions are the same as those described for Figure 3.2. 
The CE profiles of degraded and non-degraded enoxaparin are presented in 
Figure 3.6. This CE method resolved enoxaparin in to three sharp peaks followed by a 
broad peak as shown in Figure 3.6. These peaks migrated at 5.58, 5.75, 5.96 and 
6.13 minutes respectively. It is evident from the electropherograms that changes have 
occurred even during relatively mild heating of enoxaparin. With the 70 °C stressed 
sample, an extra peak at 5.98 minutes was observed. A decrease in the peak area of 
the first peak (migration time 5.58 minutes) and an increase in the peak area of the 
second peak (migration time 5.75 minutes) were observed. With the 100 °C stressed 
sample a degradation product with a migration time of 6.38 minutes was observed. 
The H20 2 stressed enoxaparin sample produced a number of new peaks accompanied 
by complete loss of the original enoxaparin peaks. This technique offers a method that 
may be suitable for pharmaceutical stability studies of various LMWHs. 
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3.4.7 CE analysis of different LMWHs and heparin 
This CE method resolved EP-LMWHS into three sharp peaks followed by two 
small broad peaks. Overlaid electropherograms of EP-LMWHS, analysed on two 
different days, are shown in Figure 3.7. As seen from the electropherograms this 
developed CE method is accurate and reproducible, as each peak ofEP-LMWHS 
migrated at the same time with identical peak areas. 
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Figure 3.7 Electropherograms of EP-LMWHS (5 mg/ml). CE conditions are the same as those 
described for Figure 3.2. 
Electropherograms of two different batches of enoxaparin are shown in 
Figure 3.8. This CE method was so sensitive that it clearly revealed differences in 6 
different regions of the electropherograms from two different batches of enoxaparin. 
These compositional differences may be due to the inherent structural variability of 
the precursor heparin from which the LMWH was derived or due to differences in the 
fractionation process. As enoxaparin is used for wide ranges of different indications, 
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the observed compositional differences in two different batches of enoxaparin may 
have clinical implications. As a dose of enoxaparin varies with different indications, 
minor compositional differences may lead to biological or clinical variability [29]. 
These results demonstrate that this method would be suitable for analysis of batch-to-
batch variation in pharmaceutical LMWHs or for "fingerprinting" batches of 
LMWHs. 
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Figure 3.8 Electropherograms of two different batches of enoxaparin with differences 
highlighted by the arrows. CE conditions are the same as those described for Figure 3.2. 
Heparin was resolved into two different peaks that migrated at 4.87 and 
7.96 minutes as shown in Figure 3.9. Although heparin contains a large number of 
different oligosaccharides, CE result suggested that these oligosaccharides fall into 
two chemically different groups. CE separation of polysaccharides is based on the 
charge of the analyte, with higher the charge earlier the migration. Peak migrated at 
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5.55 minutes represents highly charged constituents with greater degree of sulfation 
compared to constituents migrated at 8.36 minutes. 
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Figure 3.9 Electropherogram of heparin. CE conditions are the same as those described for 
Figure 3.2. 
The electrophoretic profiles of various LMWHs differed from the 
EP-LMWHS. The CE method detected major structural differences between 
dalteparin and enoxaparin. The electrophoretic profile of dalteparin (Figure 3.1) was 
more similar to its parent compound heparin compared with enoxaparin or the 
EP-LMWHS. The mean migration time of the principle peak of LMWHs and heparin 
(n=6) were 5.23 minutes (0.96% RSD; EP-LMWHS), 5.68 minutes (0.74% RSD; 
enoxaparin) and 4.87 minutes (0.63% RSD; heparin). The intra-day precision RSD of 
the principle peak ofEP-LMWHS, enoxaparin and heparin (n=6) were 3.5%, 4.0% 
and 3.2% respectively. 
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The CE method described here has several advantages over previously 
reported CE methods for intact LMWHS and heparin. Electrophoretic separation can 
be performed in less than 10 minutes for LMWHs which compares with more than 
20 minutes and 40 minutes for previous CE methods [73,74]. Using the current 
methodology, enoxaparin or EP-LMWHS were resolved or partially resolved in to 11 
or 8 different peaks compared with only 4 or 5 peaks evident in electropherograms of 
the same LMWHs using the method described by Ramasamy et al [73]. In contrast 
with previously reported methods [72-74] by the method reported here, each LMWH 
showed distinctive electropherogram features with narrow peak width and 
characteristic migration times and each LMWH could readily be distinguished from 
other LMWHs and heparin. This method could be applied to further characterise 
different LMWH constituents by comparison of results with CE analyses of 
oligosaccharide standards of known molecular weight. This method combined with 
mass spectrometry (MS) detection can allow the analysis of individual molecular 
components of LMWH and heparin, which is not possible following enzymatic or 
chemical digestion procedures prior to CE analysis [54,84-87]. 
3.5 CONCLUSION 
This work has demonstrated the advantages of the developed CE method, with 
specified length and diameter of capillary, applied voltage, ionic strength and pH of 
background electrolyte, to achieve efficient separation of LMWH and heparin. The 
CE assay performance was assessed in terms of linearity, accuracy, precision, 
selectivity and gave acceptable performance and reproducibility. This method is 
simple, quick to perform an~ gives higher resolution than other reported CE 
methodologies for intact LMWHs. This versatile method was able to clearly 
differentiate three different LMWHs and heparin, and each giving electropherograms 
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with sharp peaks at consistent migration time. This method is capable of detecting 
compositional differences between batches of the same LMWH and able to show 
degradation products of LMWHs after chemical or mild thermal stress conditions. 
This CE method potentially offers a simple and rapid analytical technique to study of 
batch-to-batch variation, the characterisation and stability testing of pharmaceutical 
LMWH and heparin. 
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CHAPTER4 
An Effective Reversed-Phase Ion-Interaction High-Performance 
Liquid Chromatography Method for the Separation and 
Characterisation of Intact Low-Molecular-Weight Heparins 
4.1. SUMMARY 
A simple, selective, reproducible and efficient reversed-phase ion-interaction 
high-performance liquid chromatography (ion-interaction RP-HPLC) method with diode array 
detection was developed, using enoxaparin as the test analyte. Acetonitrile concentration, 
different ion-interaction reagents, conce11tration of ion-interaction reagent and pH were found 
to be critical for the efficient separation. It was demonstrated that, in general, elution time 
increased with molecular weight. Suitability of the ion-interaction RP-HPLC separation was 
also demonstrated with evaporative light scattering detection (ELSD). EP-LMWHS, dalteparin 
and enoxaparin were analysed with superior resolution and peak shape compared with 
results using other analytical methods for intact LMWHs. Differences between the LMWHs 
were demonstrated. This method clearly showed chemical changes that occurred to 
enoxaparin following heat stress. The ion-interaction RP-HPLC method has potential for 
investigation of intact LMWHs. 
4.2 INTRODUCTION 
Reversed-phase high-performance liquid chromatography (RP-HPLC) is the 
most commonly used mode of partition chromatography. It consists of a non-polar 
stationary phase bonded to a solid support that is generally microparticulate silica gel 
and a polar mobile phase. It is used to separate non-polar and slightly polar species 
that are partitioned between the mobile and the stationary phases. The separation is 
normally performed using aqueous mobile phases containing different percentages of 
organic modifiers (e.g. methanol or acetonitrile) to increase the selectivity between 
species. 
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Highly negatively or positively charged analytes in RP-HPLC show little or no 
retention on lipophilic stationary phases when reversed phase eluent is used [99]. 
However, retention and subsequent separation of charged analytes on these stationary 
phases can be achieved by the addition of a reagent having the opposite charge to that 
of the analyte. The oppositely charged reagent is termed an ion-interaction reagent 
and this modified technique is called ion-interaction RP-HPLC. The ion-interaction 
reagent is a compound with a polar head group (such as ammonium or sulfate) and a 
non-polar tail (such as alkyl or phenyl). Separation in ion-interaction RP-HPLC 
depends on the stationary phase functional group, ionic strength, pH, ion-pairing 
reagent and the organic modifiers used in the mobile phase. 
The separation mechanism involved in ion-interaction RP-HPLC is not 
completely understood. There are three proposed mechanisms by which 
ion-interaction RP-HPLC facilitates separation of negatively charged analytes [99]. 
According to the ion-pair mechanism, the positively charged ion-pair reagent forms 
ion-pairs with negatively charged analyte. The resultant neutral ion-pair can then be 
adsorbed onto the lipophilic stationary phase. The degree of retention of the ion-pair 
is dependent on the lipophilicity of the ion-interaction reagent itself. An increase in 
the percentage of organic modifier in the eluent decreases the interaction of the 
ion-pairs with the stationary phase and therefore reduces their retention. According to 
the dynamic ion-exchange model, the positively charged ion-interaction reagent is 
adsorbed on the stationary phase and imparts a charge to the stationary phase, causing 
it to behave as an ion-exchanger. The total concentration of ion-interaction reagent 
adsorbed on the stationary phase is dependent on the percentage of organic solvent, 
with a lower concentration of organic solvent giving a higher concentration of the 
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ion-interaction reagent on the stationary phase. Retention of the negatively charged 
analyte on the stationary phase is based on a conventional ion-exchange mechanism. 
The ion-interaction model proposes a combination of the two previous mechanistic 
models, with ion-interaction reagent forming a dynamic equilibrium between eluent 
and stationary phase. The adsorbed positively charged ion-interaction reagent ions are 
spaced evenly over the stationary phase due to repulsion effects. The adsorbed 
ion-interaction reagent constitutes a primary charge layer, to which is attracted a 
diffuse, secondary layer of oppositely charged ions. The amount of charge in both 
primary and secondary charged layers is dependent on the lipophilicity of the 
ion-interaction reagent, the ion-interaction reagent concentration and the percentage 
,-
.. 
' 
of organic solvent in the eluent. The negatively charged analyte competes for a 
position in the secondary charge layer and then moves into the primary layer as a 
result of electrostatic attraction. The presence of negatively charged analyte into this 
layer decreases the overall charge of primary layer, so to maintain charge balance 
further ion-interaction reagent enters into the primary layer. The overall result is the 
formation of pairs of ions (that is, negatively charged analyte and positively charged 
ion-interaction reagent). 
Ion-interaction RP-HPLC has not been explored as an alternative analytical 
methodology to HP-SEC, CE or SAX for the analysis of intact LMWHs. Several 
applications of ion-interaction RP-HPLC have been employed but only for the 
analysis of smaller oligosaccharides and disaccharides from enzymatically 
depolymerised heparin [100,101] and LMWHs [102]. An efficient ion-interaction 
RP-HPLC method for the analysis of intact heparin and LMWHs would offer the 
ability to study individual constituents of the undigested polymer mixtures, potentially 
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giving important structural information relating to biological activity. This method 
would allow the study of specific changes brought about by enzymatically- or 
chemically-mediated digestion of specific heparin constituents. It would also be useful 
for pharmaceutical stability studies that can not be performed using currently 
available analytical techniques. 
Literature searches (using MEDLINE, SciFinder and Google) were unable to 
find any reports describing a versatile and efficient analytical technique for the 
characterisation of various constituents of intact LMWHs without prior 
depolymerisation or fractionation. There is an important need to have a simple and 
reproducible analytical technique for the separation of intact LMWHs with high 
resolution. For various reasons, as described below, enoxaparin was selected as a test 
analyte to develop a simple ion-interaction RP-HPLC method. Enoxaparin is the first 
approved LMWH approved by the FDA [l]. In the treatment and prevention of 
venous thrombosis enoxaparin has demonstrated its effectiveness over heparin and 
other LMWHs [26,40,55]. Among all other LMWHs, enoxaparin is commonly used in 
pediatric patients. Enoxaparin is obtained by ~-eliminative cleavage of unfractionated 
heparin resulting in a LMWH with a high polydispersity and chemical variability [20]. 
This presents a great analytical challenge and the potential for further study of many 
different constituents of enoxaparin. Several parameters were investigated such as the 
concentration of organic modifier, different ion-interaction reagents, concentration of 
ion-interaction reagent and the pH of the mobile phase. The developed ion-interaction 
RP-HPLC method was validated in terms of linearity, precision, accuracy and 
selectivity. Furthermore, this method was applied to the analysis of enoxaparin 
fractions from HP-SEC, various LMWH samples and a heat stressed enoxaparin 
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sample in order to demonstrate its potential in applications for the detailed analysis of 
intact LMWHs. 
The primary objective of this study was to develop an effective high resolution 
ion-interaction RP-HPLC method to separate intact LMWHs without 
depolymerisation or fractionation prior to analysis that allows the chemical and 
structural characterisation of individual oligosaccharides in relation to their biological 
activity. 
4.3 EXPERIMENTAL 
4.3.1 Jilaterials 
The sodium salt of enoxaparin (10 OOO IU/ml) was purchased from Aventis 
Pharma (Sydney, NSW, Australia). EP-LMWHS was from Pharmacopee Europeenne 
(Strasbourg, France). Acetonitrile, ammonium acetate, sodium sulfate, hydrochloric 
acid, acetic acid, tetrabutylammonium hydroxide (TBAH), tributylamine (TBA) and 
triethylamine (TEA) were of analytical grade and purchased from Sigma Aldrich 
(Castle Hill, NSW, Australia). 
4.3.2 High performance liquid chromatography (HPLC) instrumentation 
The HPLC system consisted of a Prostar 230 solvent delivery module, Prostar 
335 diode array detector and Prostar 410 autosampler (Varian Inc, Melbourne, VIC, 
Australia) and Alltech ELSD 2000ES detector (Alltech Associates, Sydney, NSW, 
Australia). Data acquisition and instrument control were carried out using Star 
Chromatography Workstation software. 
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4.3.3 Ion-interaction RP-HPLC separation 
Ion-interaction RP-HPLC of enoxaparin sodium was performed on a 5 µm 
Varian Microsorb C18 column (150 x 4.6 mm) (Varian Inc, Melbourne, VIC, 
Australia). The mobile phase consisted of acetonitrile, water, ion-interaction reagent 
and ammonium acetate. Diode array detection was carried out at 230 nm. For ELSD, 
nebuliser temperature and drift tube temperature were set at 100 °C. Nitrogen was 
used as a carrier gas with a flow rate of 2.0 I/minute. The detector sensitivity was set 
at gain 1 with impactor off. The analyses were performed with 30 µl or 50 µl of 
sample injection at a flow rate of 1.0 ml/minute. 
4.3.4 Method development 
Enoxaparin was diluted with mobile phase to a concentration of 1 mg/ml. 
Mobile phase contained various concentrations of acetonitrile (10% to 52%), together 
with an ion-interaction reagent [either TBAH (10, 15 or 20 mM), TBA (15 mM) or 
TEA (15mM)] and ammonium acetate (10, 25 or 50 mM). The pH was adjusted to 
3.0, 5.0 or 7.0 by the appropriate addition of acetic acid. The pH of the sample 
solutions was adjusted as described in section 3.3.2. 
4.3.5 HP-SEC separation 
HP-SEC was performed using a Shodex OHpak SB-802.5 HQ 8mm x 300 mm 
size exclusion column and Security Guard equipped with a GFC 2000 cartridge 
(Phenomenex, NSW, Australia). The mobile phase was 0.3 M sodium sulfate (pH 
adjusted to 5.0 with 0.1 M HCl) at a flow rate of 0.3 ml/minute. The EP-LMWHS for 
calibration with a number average molecular mass of 3 700 was analysed. Enoxaparin 
was similarly analysed and in addition 20 different fractions (each fraction of 150 µl) 
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eluting between 18 and 28 minutes were collected. Each collected fraction was 
reanalysed by HP-SEC for peak distribution confirmation and selected fractions were 
then reanalysed by ion-interaction RP-HPLC. 
4.3.6 Assay Performance 
Intra- and inter-day precision (over five consecutive days) were investigated 
using peak areas, from 5 different arbitrarily chosen peaks, with repeated analysis of 1 
mg/ml enoxaparin solution. Mean intra- and inter-day accuracy was calculated as 
follows; (observed concentration - expected concentration)/expected concentration 
xlOO. Mean intra- and inter-day peak retention time was also determined. 
4.3.7 Analysis of stressed enoxaparin 
Enoxaparin solution (100 mg/ml, 50 µl) was subjected to thermal stress in 
sealed N2-filled 1 ml glass ampoules, but the solution was not degassed. Enoxaparin 
solution was heated at 70 °C for 6 hours. Ion- interaction RP-HPLC analyses were 
performed on both stressed and unstressed samples for comparative purposes. 
4.3.8 Preparation of various LMWHs samples 
Enoxaparin (10 OOO IU/ml), EP-LMWHS and dalteparin (12 500 IU/ml) were 
diluted to 1 mg/ml with mobile phase before ion-interaction RP-HPLC or HP-SEC 
analysis. Each sample was analysed six times to test the reproducibility of the 
technique. 
52 
Chapter4 
4.4 RESULTS AND DISCUSSION 
4.4.1 Effect of acetonitrile concentration 
The elution behaviour of enoxaparin was investigated under different isocratic 
conditions in which the concentration of acetonitrile was systematically changed over 
the range 52% to 30%. Ammonium acetate (50 rnM) and TBAH (15 rnM) 
concentrations at pH 7 .0 were kept constant. Chromatograms of enoxaparin obtained 
using different concentrations of acetonitrile are shown in Figure 4.1. The highest 
studied concentration of acetonitrile ( 52 % ) failed to separate enoxaparin. The 
chromatographic resolution of enoxaparin was only slightly affected by the 
concentration of acetonitrile between 52% to 39%. However, a small decrease in the 
acetonitrile concentration from 39% to 36% had a remarkable effect on the 
separation of enoxaparin. Mobile phase containing 36% acetonitrile resolved 
enoxaparin into more than 15 different peaks compared to two peaks obtained using 
eluent containing 39% acetonitrile. However, with 36% acetonitrile concentration, 
overlapping peaks were observed and resolution was further improved by decreasing 
the acetonitrile concentration to 33%. Resolution of the early eluted peaks (between 
1.0 and 10 minutes) with 33% acetonitrile was improved by decreasing the 
concentration of acetonitrile by 1.0%. The lowest studied acetonitrile concentration 
(30%) gave a similar resolution to that of 32% but with analysis taking more than 90 
minutes, resulting in no additional chromatographic benefits. An acetonitrile 
concentration of 32% was selected for further method development. 
The amount of ion-interaction reagent adsorbed onto the surface of the 
stationary phase is influenced by the concentration of organic modifiers [103]. The 
vastly different resolution and retention times, between mobile phase containing 39% 
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Figure 4.1 The influence of various concentrations of acetonitrile on the ion-interaction 
RP-HPLC separation of enoxaparin. Experimental conditions: Varian C18 (150 x 4.6 mm), 
5 µm column; eluent containing acetonitrile-water (as specified in chromatograms); TBAH 
(15 mM); ammonium acetate (50 mM); pH 7.0; detection wavelength 230 nm; flow rate 
1 ml/minute; injection volume 30 µI. 
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and 36% acetonitrile, indicated a large change in the relative affinities of the mobile 
and stationary phases for the negatively charged polysaccharide molecules of the 
analyte over this acetonitrile concentration range. This change may be due to a large 
increase in the adsorption of the ion-interaction reagent to the stationary phase at 36% 
compared with 39% acetonitrile concentration. This increased adsorption of the 
ion-interaction reagent on the stationary phase would result in increased interaction 
between analyte and the stationary phase resulting in a large impact on the retention 
and resolution of enoxaparin polysaccharides. 
4.4.2 Effect of the ion-interaction reagent 
Enoxaparin is a highly negatively charged polysaccharide, which makes it 
difficult to retain and resolve on a C1s column in the absence of an ion-interaction 
reagent. Three different ion-interaction reagents, TEA, TBA and TBAH were 
investigated to determine their ion-interaction capacity and hence the effect on 
chromatographic separation. It was attempted to determine the optimal acetonitrile 
concentration for each of the ion-interaction reagents by steadily reducing the 
acetonitrile concentration until satisfactory resolution was achieved within a 
reasonable time frame (90 minutes). As seen from Figure 4.2, TEA failed to resolve 
enoxaparin at even 10% acetonitrile concentration. TBA at 20% acetonitrile 
concentration gave separation of early eluting peaks but did not resolve the late 
eluting peaks. TBAH successfully resolved both the early and late eluting peaks at 
32% acetonitrile concentration making it a preferable ion-interaction reagent for the 
analysis of intact enoxaparin over TBA. 
Alkyl chain length and the bulk structure of the ion-interaction reagent are 
important parameters in ion-interaction chromatographic separations [104]. The 
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Figure 4.2 the effect of different ion-interaction reagents at 15 mM concentration on the 
chromatographic separation of enoxaparin. Experimental conditions are the same as those 
described in Figure 4.1 except for the eluent which contained 10%, 20% or 32% acetonitrile 
for TEA, TBA and TBAH respectively. 
56 
Chapter4 
longer the alkyl chain and the greater the bulk structure the more hydrophobic the 
counter ion and the greater the retention. Acetonitrile in the eluent decreases the 
effective capacity of the C1s column at higher concentrations. The effectiveness of 
TBAH at higher concentrations of acetonitrile, compared with TBA and TEA, could 
be explained by its greater hydrophobicity. 
4.4.3 Influence of TBAH concentration on the separation parameters 
The effect of cationic ion-interaction reagent on the separation parameters was 
investigated in the 10 mM to 20 mM concentration range. The optimal concentration 
of acetonitrile for each TBAH concentration was first investigated before the 
comparison of chromatographic resolution was made. A remarkable TBAH 
concentration-dependent effect on the separation and on the peak retention time was 
observed. As seen from Figure 4.3. at 10 mM TBAH concentration, more than 15 
different peaks were observed, however the early eluting peaks were poorly resolved 
and peak tailing and broadening of later-eluting peaks were observed. Enoxaparin was 
successfully resolved using 15 mM TBAH with satisfactory resolution and peak 
shape. When 20 mM TBAH was used, retention times increased and peaks were 
broader. 
The resolving power of cationic ion-interaction reagents is solely due to their 
interaction with the ionisable groups of the analyte. This resolving power increases 
with an increase in the concentration of the ion-interaction reagent. With the current 
system, increased retention times limited the useful concentration of ion-interaction 
reagent to 15 mM; hence this concentration was chosen for further chromatographic 
separations. 
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Figure 4.3 The effect of different concentrations of TBAH on the separation of enoxaparin. 
Experimental conditions are the same as those described in Figure 4.1 except for the eluent 
which contained 28%, 32% or 34% acetonitrile for 10 mM, 15 mM and 20 mM TBAH 
respectively, which were found to be the optimum concentration of acetonitrile for each 
ion-interaction reagent. 
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4.4.4 Influence of pH and ammonium acetate concentration 
The mobile phase containing 32% acetonitrile, 15 mM TBAH and 50 mM 
ammonium acetate at different pH values ranging from 3.0 to 7.0 was investigated to 
study the effect of pH on the separation of enoxaparin sodium. Higher pH values 
enhanced the chromatographic separation of enoxaparin, especially of the late eluting 
peaks. The pKa values of 0-sulfo, N-sulfo and carboxy groups in heparin are greater 
than 1.0, 1.5 and 3.0 respectively [105]. The negative charge and pKa values increase 
with larger polymer size [105]. Thus smaller oligosaccharides may be completely 
ionised at pH 5.0 but a higher pH is required for complete ionisation of larger 
polymers. Enhanced resolution at pH 7 .0 is probably because complete ionisation of 
both sulfo and carboxy groups allowed their greater interaction with cations of the 
ion-interaction reagent. 
Mobile phase containing different concentrations of ammonium acetate was 
investigated. Mobile phase without ammonium acetate did not provide satisfactory 
chromatographic resolution. As shown in Figure 4.4, increased concentration of 
ammonium acetate improved the separation of enoxaparin fractions and adequate 
resolution was achieved with the use of 50 mM ammonium acetate. Hence mobile 
phase consisting of acetonitrile-water (32:68), 50 mM ammonium acetate and 15 mM 
TBAH at pH 7 .0 was selected for the assay performance investigation. 
4.4.5 Ion-interaction RP-HPLC analysis of HP-SEC enoxaparin fractions 
The HP-SEC chromatograms ofEP-LMWHS and enoxaparin are shown in 
Figure 4.5A. HP-SEC resolved or partially resolved the EP-LMWHS into 8 different 
peaks (labelled a to h). The composition of the oligosaccharides corresponding to the 
EP-LMWHS HP-SEC peaks have previously been reported [106]. By comparison of 
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Figure 4.4 The effect of different concentrations of ammonium acetate on the separation of 
enoxaparin. Experimental conditions are the same as those described in Figure 4.1 with the 
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Figure 4.5 HP-SEC analysis of EP-LMWHS, enoxaparin (A) and HP-SEC collected fractions 
of enoxaparin (B). Peaks b-h represent tetradeca-, dodeca-, deca-, octa-, hexa-, tetra- and 
di-saccharides respectively. Experimental conditions: Shodex OHpak SB-802.5 HQ 
8mm x 300 mm size exclusion column, Security Guard column equipped with a GFC 2000 
cartridge, eluent containing 0.3 M sod ium sulfate (pH 5.0) , detection wavelength 230 nm , flow 
rate 0.3 ml/minute, injection volume 30 µI. 
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Figure 4.6 Ion-interaction RP-HPLC analysis of HP-SEC enoxaparin fractions 8 (A), 10 (B), 12 (C), 13 (D) and 18 (E), mainly composed of dodeca-, deca-, 
octa-, hexa- and tetra-saccharides. Ion interaction RP-HPLC was carried out under the same conditions as described in Figure 4.1 with eluent containing 32% 
acetonitrile. 
62 
c 
80 
Chapter4 
the EP-LMWHS peaks with the enoxaparin peaks, it was possible to assign the 
oligosaccharide composition of each enoxaparin peak. Reanalysis by HP-SEC of 20 
different fractions of enoxaparin collected using HP-SEC showed that fractions 8, 10, 
12, 13 and 18 contained of dodeca-, deca-, octa- and hexa-saccharides respectively 
with some overlap between fractions as shown in Figure 4.5B. No additional attempts 
were made to purify the enoxaparin fractions prior ion- interaction RP-HPLC 
analysis. Ion-interaction RP-HPLC chromatograms of fractions 8, 10, 12, 13 and 18 
are presented in Figure 4.6. It can be seen that the larger oligosaccharides eluted later 
by ion-interaction RP-HPLC. This developed method was able to resolve each group 
of oligosaccharides into several different peaks. As seen from Figure 4.6A, ion-
interaction RP-HPLC separated fraction 8, mainly composed of dodecasaccharides, 
into four distinct peaks. The chromatogram of fraction 10 (Figure 4.6B) showed, in 
addition to the peaks observed in fraction 8, three additional peaks due to 
decasaccharides. Fraction 12 (Figure 4.6C) showed one sharp peak followed by two 
small peaks of octasaccharides. Fraction 13 (Figure 4.6D), enriched with 
hexasaccharides, was separated into eight different peaks. The chromatogram of 
fraction 18 (Figure 4.6E) containing tetrasaccharides, showed four different peaks in 
addition to the peaks of fraction 13. Unlike the HP-SEC technique for the analysis of 
intact LMWHs, this ion-interaction RP-HPLC methodology is capable of 
distinguishing between different oligosaccharides of similar molecular weight as well 
as separating smaller oligosaccharides from larger oligosaccharides. As the chemical 
and biological properties of different oligosaccharides vary with their molecular 
weight, the high resolution of this technique offers a potential method for the 
separation of intact oligosaccharides to enable their structural characterisation and 
biological activity determination. This can be achieved by preparative collection of 
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different LMWH fractions by ion-interaction RP-HPLC. These fractions can be 
analysed by ion-interaction RP-HPLC-MS and low-volume microtitre plate 
chromogenic assay for structural and biological activity information. 
4.4.6 Assay performance 
The assay performance was determined using 5 different arbitrarily chosen 
peaks within the enoxaparin chromatogram and results are shown in Table 4.1. Peak 
areas were obtained using peak valley (trough) baseline determinations. The intra- and 
inter-day precision RSD for each peak was less than 5.0% (n=6) and 6.1 % (n=5) 
respectively at the level of 1 mg/ml enoxaparin. The intra- and inter-day accuracy 
RSD for each peak was less than +5.6% and +6.5% respectively at 1 mg/ml 
enoxaparin. Intra- and inter-day retention time RSD for each of the 5 arbitrarily 
selected enoxaparin peaks were less than 0.61 % (n=6) and 2.17% (n=5) respectively. 
4.4.7 Ion-interaction RP-HPLC analysis using ELSD 
Enoxaparin was separated by ion-interaction RP-HPLC using a mobile phase 
containing 15 mM TBA, 32% acetonitrile and 50 mM ammonium acetate at pH 7.0. 
Flow was split immediately after the column using a T-piece to allow simultaneous 
detection by ELSD and UV. Chromatograms obtained by ELSD and UV are shown in 
Figure 4.7. Similar chromatographic signals were observed with both detectors except 
for an additional early ELSD signal attributable to salts. TBA allows the option of 
ELSD detection, whereas TBAH is not sufficiently volatile for ELSD. The TBA 
method could be further optimised for ELSD applications, to enhance resolution, 
particularly if a later, more sensitive ELSD was used. The advantage of ELSD, 
compared with UV, is that peak areas are not dependent on UV chromophores, for 
which extinction coefficients can vary by orders of magnitude, depending on the 
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Table 4.1 RP-HPLC assay performance determined by analysis of five enoxaparin peaks. 
Peak number Retention time Peak Area Precision (% RSD) Accuracy (% RSD) Retention time (% RSD) 
lntra-daya lnter-dal Intra-day Inter-day Intra-day Inter-day 
1 6.39 79573 2.33 4.88 5.27 6.40 0.42 2.17 
2 10.45 489277 4.91 5.36 5.58 5.92 0.60 1.39 
3 19.46 1436578 4.56 5.78 3.48 4.96 0.11 0.67 
4 28.58 146817 4.89 6.08 0.13 0.19 0.39 0.98 
5 51.52 265300 4.06 5.90 2.26 3.20 0.30 0.53 
a for all intra-day, n=6 b for all inter-day n=5 
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chemistry of the analyte, but are more dependent on the mass of analyte present. No 
ion-interaction RP-HPLC methods with ELSD detection have previously been 
reported for heparin or its low molecular weight derivatives. As ELSD compatible 
methods are also compatible with MS, this method could easily be applied for MS 
detection. The combination of ion-interaction RP-HPLC with mass spectrometry 
detection has the potential to provide both molecular weight and structural 
information of various LMWH oligosaccharides. 
0 5 10 15 20 25 30 35 
Retention time (minutes) 
Figure 4.7 Ion-interaction RP-HPLC chromatograms of enoxaparin with simultaneous ELSD 
and UV detection. Experimental conditions for UV detection are the same as those described 
in Figure 4.1 except for the eluent, which contained 32% acetonitrile and 15 mM TBA. Details 
of ELSD operational conditions are given under methods. 
4.4.8 Analysis of stressed enoxaparin solution 
The ion-interaction RP-HPLC chromatograms of thermally stressed and 
unstressed enoxaparin samples are presented in Figure 4.8. The developed 
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ion-interaction RP-HPLC method has clearly demonstrated the changes that occurred 
in enoxaparin during heating at 70 °C for 6 hours. It is evident from Figure 4.8 that 
enoxaparin undergoes chemical changes, particularly after relatively mild thermal 
treatment, to the lower molecular weight fractions. This analytical technique offers a 
method that can be applied to pharmaceutical stability analysis of various intact 
LMWHs. 
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Figure 4.8 Ion-interaction RP-HPLC chromatograms of enoxaparin before and after stressing 
at 70 °C for 6 hours with the main differences highlighted by the arrows. Ion-interaction 
RP-HPLC conditions are the same as those described in Figure 4.6. 
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4.4.9 Ion-interaction RP-HPLC analysis of different LMWHs 
The chromatograms of dalteparin, enoxaparin and EP-LMWHS are shown in 
Figure 4.9. Each LMWH showed distinctive chromatographic features with narrow 
peaks, good resolution and characteristic migration times and each LMWH could 
readily be distinguished from other LMWHs. The ion-interaction RP-HPLC method 
clearly demonstrated the presence of chemically distinct constituents in dalteparin 
(prepared by deaminative cleavage) in comparison with constituents of enoxaparin 
and EP-LMWHS (both prepared by B-elimination). The chromatograms of enoxaparin 
and EP-LMWHS show some common peaks and other peaks found in one or the 
other, despite sharing similar molecular weight distribution profiles by HP-SEC and a 
similar preparation method. Ion-interaction RP-HPLC analysis showed the presence 
of more disaccharides and tetrasaccharides in EP-LMWHS than in enoxaparin. High 
levels of these lower mass oligosaccharides are also evident by HP-SEC analysis 
(Figure 4.5A). 
This developed method has several advantages over other analytical 
techniques for the separation and characterisation of intact LMWHs. It successfully 
resolved both lower (less than 2 OOO Da) and higher (more than 5 OOO Da) molecular 
weight oligosaccharides of intact LMWHs compared with the previously reported 
SAX methodology [54] that failed to resolve higher molecular weight 
oligosaccharides and showed broad peaks with poor resolution. 
The CE procedures for the separation of intact LMWHs using different 
buffers have limitations associated with poor peak shape and inadequate resolution. 
For example, analysis of dalteparin by CE showed one broad peak with a few minor 
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Figure 4.9 Ion-interaction RP-HPLC chromatograms of dalteparin, EP-LMWHS and enoxaparin. Experimental conditions are the same as those described in 
Figure 4.6. 
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semi-resolved peaks [73]. Most reported HP-SEC methods failed to resolve dalteparin 
into more than two different peaks [72,76]. The HP-SEC method demonstrated by 
Mulloy et al resolved dalteparin into eight different peaks [10]. PAGE analysis of 
dalteparin gave only a few defined bands [72]. The RP-HPLC method described here 
gave more than 16 well resolved peaks for dalteparin. 
HPLC is available in most laboratories, the method is relatively quick and can 
be automated and has the potential, by careful selection of organic modifier 
concentration, ion-interaction reagent and its concentration, for fine tuning for 
specific applications, such as enhanced resolution of lower or higher mass 
oligosaccharides. Gradient elution techniques may also allow the development of 
more versatile analyses for some applications. The ELSD-compatible ion-interaction 
RP-HPLC method may also be suitable for detection by mass spectrometry. 
4.5 CONCLUSION 
An ion-interaction RP-HPLC method was developed for the separation of 
LMWHs using a standard 150 mm column containing 5 µm C1s stationary phase and 
an eluent containing acetonitrile-water (32:68), 15 mM TBAH and 50 mM 
ammonium acetate at pH 7.0. This methodology is relatively quick and gives 
resolution superior to previously reported methods for the analysis of intact LMWHs. 
The method showed differences and similarities between different LMWHs. It also 
showed changes resulting from heat stress of enoxaparin. The potential application of 
the ion-interaction RP-HPLC method coupled to ELSD was also demonstrated. 
Ion-interaction RP-HPLC of intact LMWHs is a powerful and versatile technique that 
can allow identification of LMWHs or their constituents by comparison with 
authenticated standards; the chemical characterisation and pharmaceutical stability 
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determination of various intact LMWHs; and can be applied to the investigation of 
changes to individual oligosaccharides present in LMWH formulations. 
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CHAPTERS 
Investigation of Freezing- and Thawing-Induced Biological, 
Chemical and Physical Changes to Enoxaparin Solution 
5.1 SUMMARY 
This study investigated the effect of freezing and thawing on the biological, physical 
and chemical properties of enoxaparin solution. Solutions were frozen and thawed under 
different conditions, in the presence or absence of dimethyl sufoxide (DMSO) or 
1,2-propanediol (1,2-PD), and the AFXa activity was determined. Enoxaparin solution lost 
more than 60% of its AFXa activity when thawed rapidly after freezing at -196 °C. The loss of 
AFXa activity was less with higher freezing temperatures and increased with the number of 
freeze/thaw cycles, but was independent of the duration of freezing. Slow freezing to -196 °C 
with rapid thawing, or rapid freezing with slow thawing, resulted in negligible loss of AFXa 
activity. The loss of AFXa activity did not involve the loss of N-sulfate groups, the breakdown 
of glycosidic bonds, water crystal formation or the glassy state transition. Controlling the 
freezing or thawing conditions, dilution with water or addition of a small percentage of DMSO 
ameliorated the loss of enoxaparin AFXa activity. The loss in AFXa activity was found by 
HP-SEC to be primarily due to aggregation and was reversed by sonication in the presence of 
DMSO. These results may provide insight into solutions for the long-term storage of 
concentrated or diluted enoxaparin. 
5.2 INTRODUCTION 
Enoxaparin is obtained by controlled alkaline depolymerization of the benzyl 
ester of natural porcine heparin. This process results in the formation of lower 
molecular weight chains of which 15-25% contains a 1,6-anhydro-glucosamine at the 
reducing end. The presence of this structural feature, unique to enoxaparin among 
LMWHs, decreases AFXa activity minimally [107]. N-sulfo and 0-sulfo groups 
present in the pentasaccharide sequence are important for maintaining the 
anticoagulant activity of heparin [6,15,108,109]. 
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Commercial enoxaparin is available as a 100 mg/ml solution, which is stored 
below 25 °C and is not to be frozen. Other polysaccharides such as carrageenan, 
carboxymethyl cellulose and sodium alginate are added to various frozen food 
formulations. They are believed to protect the food product from the development of 
coarse texture as a result of ice recrystallization or growth during heat shock 
[110,111]. There has been little published on the freezing behaviour of heparin 
solutions or, more generally, of sulfated oligosaccharides. By comparison there is an 
extensive literature associated with the freezing and thawing of protein solutions, the 
subject of a recent review [112]. In general, for enzymes, it has been found that rapid 
freezing followed by rapid thawing results in the greatest retention of enzymatic 
activity. When an aqueous solution freezes, ice crystal formation results in 
concentration of the solute in the spaces between the ice crystals (freeze 
concentration). This can give rise to numerous consequences, including changes in 
pH, crystallisation of solutes, and phase separation between incompatible constituents. 
When no further ice formation can take place, the maximally concentrated solute 
forms a rigid glassy solid [112]. The more rapid the freezing the smaller the ice 
crystals formed and the greater the total ice crystal surf ace area. These results in a 
large ice:freeze-concentrate interfacial area. Hence, freeze/thaw treatment has the 
potential to induce chemical and physical changes to solutes that may be dependent 
on the rates of freezing and thawing and may involve freeze concentration, ice 
formation, glassy-state transitions or other processes. 
A search of MEDLINE and SciFinder databases was conducted to determine 
the effect of freezing or long-term storage on the activity of LMWHs, or more 
generally, on heparin. The search found one study related to heparin activity at long-
term storage [113]. This study reported formation of aggregates in heparin solution. 
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Size distribution or aggregation of various proteins compared with polysaccharides 
has been extensively studied using different analytical methods. These includes HP-
SEC [114-118], analytical ultracentrifugation [119-121], field flow fractionation [122-
123], HP-SEC with online multiple laser light scattering (MALLS) [124-126], quasi-
elastic laser scattering techniques [113, 127-128], MS [129-130], electrophoresis 
[131], fluorescence correlation spectroscopy [132] and others [133-134]. 
HP-SEC is a simple, fast and convenient technique for the detection of 
aggregates [115-118]. The major problem associated with HP-SEC detection is the 
elution time of the analyte, which may change if the analyte interacts with the column 
matrix [135-136]. HP-SEC is not capable of distinguishing between different 
oligosaccharides of similar molecular mass [77]. Analytical ultracentrifugation is 
widely used for the determination and analysis of various aggregates, especially 
macromolecules. It is routinely used to study the nature of soluble protein aggregates 
in pharmaceutical formulations [119-120]. Application of HP-SEC in the study of 
pharmaceutical aggregates is sometimes restricted as it requires a mobile phase that is 
different and may not be compatible with the formulation [137]. Successful use of 
field flow fractionation has been reported in separation of protein aggregates. Unlike 
HP-SEC, field flow fractionation uses an empty channel instead of a column matrix to 
avoid interaction with the analyte [137-138]. HP-SEC - MALLS has been 
successfully used for the quantification of soluble aggregates. The advantage of this 
combination technique is that the determination of molecular weight is not dependent 
on the retention time of the analyte, but rather based on its refractive index [124-126, 
136]. The use of quasi-elastic laser scattering or its combination with other techniques 
for the analysis of particle size distribution or changes in radius of gyration has been 
reported. This technique is quick and reliable for the analysis of large aggregated 
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molecules [139]. Decker et al have reported aggregation of lignin at pH below 8.5 by 
quasi-elastic laser scattering which was not observed using UV and refractive index 
detectors [140]. Various MS approaches have been employed for the accurate 
molecular weight analysis of different aggregates. This technique has outperformed 
many conventional techniques such as gel electrophoresis [129-130]. 
A preliminary study associated with stability testing found a significant loss in 
AFXa activity of frozen/thawed enoxaparin solution. Increased clinical interest in 
LMWHs, the intriguing behavior of frozen solutions of polysaccharides and the 
observed loss of AFXa activity following freezing underline the need to improve the 
understanding of the behavior shown by enoxaparin under different freezing 
conditions. By developing an understanding of the freezing process of enoxaparin 
solution, and the loss of anticoagulant activity, it was postulated that it may be 
possible to develop a method for the long-term storage of concentrated or diluted 
enoxaparin solutions. 
The purpose of the study was to explore the effects of freezing and thawing on 
the AFXa activity of enoxaparin solution, to investigate freezing- and thawing-
induced chemical and physical changes and to develop methods to ameliorate the 
freezing- and thawing-induced loss in the AFXa activity of enoxaparin. 
5.3 EXPERIMENTAL 
5.3.1 Materials 
The sodium salt of enoxaparin (100 mg/ml) was purchased from Aventis 
Pharma (Sydney, Australia) and used as supplied at pH 7.0. The AFXa activity 
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kit# 832 was from American Diagnostica Inc. (Stamford, CT, USA). the 
bicinchoninic acid (BCA) assay kit to determine reducing capacity and fluoraldehyde 
assay reagent to measure free amino groups were from Pierce (Rockford, IL, USA). 
N-acetyl-D-glucosamine, Dimethyl sulfoxide (DMSO), 1,2-propanediol (1,2-PD), 
sodium sulfate, hydrochloric acid and glycine were of analytical grade and all other 
chemicals were of reagent grade from Sigma Aldrich (Castle Hill, NSW, Australia). 
Microtitre plates were flat-bottomed polystyrene plates from Corning (Corning, NY, 
USA). Cryogenic tubes were from InterMed (Roskilde, Denmark). 
5.3.2 Analysis of AFXa activity 
The activity of enoxaparin solution was determined using the AFXa 
chromogenic assay kit as described in section 2.3.2. The AFXa activity of enoxaparin 
samples was determined in triplicate. 
5.3.3 Freezing of enoxaparin solution at different temperatures 
Enoxaparin solution (100 mg/ml, 50 µl) was frozen at different temperatures 
below 0 °C. Liquid thermostat baths were produced by using a stirred solid-liquid 
mixture at its melting point. The solvents n-pentane, isobutyl alcohol, acetone and 
chlorobenzene were used to attain temperatures of -130 °C,-108 °C, -95 °C and -45 °C 
respectively. Solvent was placed in a polystyrene-insulated beaker and liquid nitrogen 
was added with gradual stirring to make a slurry mixture. Enoxaparin solution (10 µl) 
was added to a cryogenic tube, precooled in the slurry mixture, and frozen in the bath. 
The samples were kept in the freezing mixture for 5 minutes. Samples were similarly 
frozen in liquid nitrogen at -196 °C. Standard laboratory freezers were used to freeze 
samples at -80 °C, -26 °C and -12 °C. Cryogenic tubes containing enoxaparin solution 
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frozen at different temperatures were placed in a polystyrene tray and allowed to thaw 
at ambient temperature. The AFXa activity of these and control samples of unfrozen 
enoxaparin was determined. 
5.3.4 Repeated freeze/thaw cycles 
The effect of repeated freeze/thaw cycles on the AFXa activity was examined 
as follows. Enoxaparin solution (100 mg/ml) in a cryogenic tube was frozen at 
-196 °C in liquid nitrogen and held at that temperature for 5 minutes. The sample was 
thawed at ambient temperature. The freeze/thaw cycle was carried out repeatedly. 
Aliquots of enoxaparin solution (2 x 5 µl) were removed from the vial after every 5 
freeze/thaw cycles, up to a total of 50 cycles. 
The effect of freezing time on the AFXa activity was examined. Aliquots 
(10 µl) of enoxaparin solution (100 mg/ml) were transferred to cryogenic tubes and 
frozen in liquid nitrogen. Samples were removed from liquid nitrogen and thawed 
after frozen storage times of 1, 12, 24, 72, 120 and 168 hours. The AFXa activity of 
these and control samples of unfrozen enoxaparin was determined. 
5.3.5 Different freezing and thawing conditions 
After fast freezing, the subsequent thawing of enoxaparin solution was carried 
out under rapid or slow conditions. Under fast freezing/rapid thawing conditions, 
10 µl aliquots of enoxaparin solution (100 mg/ml) in cryogenic tubes were frozen in 
liquid nitrogen for 5 minutes and allowed to thaw at room temperature in a 
polystyrene tray. Under fast freezing/slow thawing conditions, identical enoxaparin 
samples were frozen in liquid nitrogen as before and the samples were then kept in 
freezers, first at -80 °C for 12 hours, then at -26 °C for another 12 hours, and finally 
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at -12 °C for 12 hours. After this, the samples were allowed to thaw on ice at 0 °C 
before AFXa activity analysis. The effect of slow freezing with rapid thawing to room 
temperature was investigated by freezing small aliquots (10 µl) of enoxaparin solution 
(100 mg/ml) in cryogenic tubes at -12 °C for 12 hours. The samples were then stored 
in freezers at -26 °C for 12 hours and -80 °C for 12 hours and finally in liquid 
nitrogen for 12 hours. After this, the samples were removed from liquid nitrogen and 
allowed to thaw at room temperature in a polystyrene tray before AFXa activity 
determination together with controls consisting of unfrozen enoxaparin. 
5.3.6 Dilution of enoxaparin solution prior to freezing 
The effect of dilution prior to freezing on the AFXa activity was investigated 
by diluting enoxaparin solution (100 mg/ml) 2, 5, 10 and 100 times with deionized 
water. Aliquots of each solution (20 µl) were transferred into four cryogenic tubes. 
Three were frozen in liquid nitrogen and thawed after five minutes, and one was kept 
as a control. Samples and controls were analysed for AFXa activity. 
5.3.7 Analysis of free sulfate 
Determination of free sulfate in unfrozen and freeze/thawed enoxaparin 
solution was carried out by a previously described ion chromatographic method [141]. 
Analyses were performed with a Dionex DX-120 instrument (Dionex Corporation, 
Sunnyvale, CA, USA), which consisted of a GP50 gradient pump, CD25 conductivity 
detector and AS50 auto sampler. A Dionex IonPac AS 11 column was used with a 
mobile phase gradient of water and KOH. Hydroxide eluent gradients were generated 
online using the Dionex EluGen II KOH cartridge, from 1 rnM to 15 rnM over 
15 minutes. Detection was carried out by conductivity in the suppression mode with a 
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flow rate of 1 ml/minute and injection volume of 25 µ1. Instrument control and data 
acquisition were performed using Chromeleon software. A standard plot was prepared 
using sodium sulfate containing 0 to 20 µg/ml of sulfate. 
5.3.8 Analysis of free amino groups 
The determination of free amino groups in unfrozen and freeze/thawed 
enoxaparin solution was determined by a sensitive :fluoraldehyde-based assay [142]. 
Sample (20 µl) was mixed with deionized water (180 µl) and :fluoraldehyde assay 
reagent (1 ml) was added and mixed well. The :fluorescence of each sample was 
measured at 455 nm after excitation at 360 nm using a :fluorescence 
spectrophotometer Model 1605-lOS (Perkin-Elmer, Tokyo, Japan). A standard plot 
was prepared using glycine in the range of 0 to 600 µg/ml. 
5.3.9 Analysis of reducing capacity 
The reducing capacity of enoxaparin solution frozen at -196 °C and thawed at 
room temperature and unfrozen controls was determined by a previously described 
assay [143]. Assay reagent C was prepared by mixing 50 parts of reagent A, 
consisting of sodium carbonate, sodium bicarbonate, BCA detection reagent and 
sodium tartrate in O. lN sodium hydroxide, with 1 part reagent B containing BCA. 
Sample (20 µl) was added to assay reagent C (100 µl) and mixed well for 3 minutes in 
a microtitre plate. The absorbance was measured at 560 nm using a Bio-Rad 
microplate reader Model-680 (Bio-Rad laboratories, Hercules, CA, USA). A standard 
plot was generated using N-acetyl-D-glucosamine in the range of 0 to 10 mg/ml. 
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5.3.10 Scanning electron microscopy analysis 
Microscopic evaluation was carried out using a Philips XL20 scanning 
electron microscope (Philips Electron Optics, Eindhovan, Netherlands). Scanning 
electron microscopy (SEM) stubs were cooled to -196 cc for 5 minutes. A drop of 
enoxaparin solution (100 mg/ml) was placed on the stub and allowed to freeze. The 
stub holding the frozen sample was placed on a cold table (-5 cc) and observed by 
SEM. Visual comparisons were made with similarly-frozen water. 
5.3.11 Determination of glass transition temperature 
Modulated differential scanning calorimetry (DSC) was performed using a 
Model 2920 calorimeter (TA Instruments, Newcastle, DE, USA) to determine the 
glass transition temperature (Tg) of enoxaparin solution. Samples of enoxaparin 
solution (100 mg/ml) were cooled to -130 cc in one of three ways: rapid quenching; 
cooled at a rate of -5 cc/minute; cooled at a rate of-20 cc/minute. Samples were held 
at -130 cc for 5 minutes before heating at 10 cc/minute to 30 cc. Analyses were 
performed in duplicate. 
5.3.12 Effects of cryoprotectants 
Enoxaparin solution was diluted with DMSO or 1,2-PD to obtain enoxaparin 
stock solutions containing 5% v/v of DMSO or 1,2-PD. The stock solution was 
serially diluted with enoxaparin solution (100 mg/ml) to achieve concentrations of 
1.0, 0.2, 0.04 and 0.008% of each cryoprotector in enoxaparin solution. Aliquots of 
each solution were transferred to cryogenic tubes, frozen in liquid nitrogen for 
5 minutes and thawed at room temperature. Frozen and thawed samples, with 
corresponding controls, were analyzed for AFXa activity. 
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5.3.13 Sonication of enoxaparin solution after freeze/thaw treatment 
A cryogenic tube containing 200 µl of enoxaparin solution (100 mg/ml) was 
frozen in liquid nitrogen and thawed at room temperature. After 5 freeze/thaw cycles, 
aliquots (5 µl) were diluted with 0%, 0.1%or1 % DMSO in normal saline (995 µl). 
Half the aliquots were sonicated in a Sanophon ultrasonic processor (Ultrasonic 
Industries, Tasmania, Australia) for 15 minutes and the corresponding controls were 
not sonicated. Solutions were analyzed for AFXa activity. Comparisons of AFXa 
activity between frozen samples with 0%, 0.1 % and 1 % DMSO were performed by 
one way analysis of variance (ANOV A), followed by a fishers protected least squares 
difference (PLSD) post hoe test for different conditions. Results were considered 
statistically significant with p<0.05. 
5.3.14 HP-SEC analysis 
HP-SEC was used to obtain comparative chromatographic profiles of samples 
frozen in liquid nitrogen and thawed at room temperature, before and after sonication 
in the presence and absence of DMSO and controls. HP-SEC analysis of samples was 
performed as described in section 4.3.5. 
5.4 RESULTS AND DISCUSSION 
5.4.1 Effects of freezing and thawing on AFXa activity 
The loss of AFXa activity after freezing at different temperatures is shown in 
Figure 5.1. Loss in AFXa activity occurred when enoxaparin solution was frozen at or 
below -26 °C. By comparison, samples frozen at -12 °C displayed no loss of AFXa 
activity. Enoxaparin lost 67% and 14% of control AFXa activity after freezing at 
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-196 °C and -26 °C respectively. The lower the temperature of freezing the greater 
was the loss of AFXa activity. 
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Figure 5.1 The effect of freezing at different temperatures on the AFXa activity of enoxaparin 
(n=6, error bars represent ± SD). 
The effects of repeated freeze/thaw cycles, the duration of freezing time, and 
the freezing and thawing rates on AFXa activity are presented in Figure 5.2. It can be 
seen from Figure 5.2A that the AFXa activity decreased with increasing number of 
freeze/thaw cycles and that only 13% of the initial AFXa activity remained after 
50 freeze/thaw cycles. Figure 5.2B shows that the duration of the time of freezing 
made no difference to the loss in AFXa activity. Figure 5.2C shows that fast freezing 
with rapid thawing resulted in enoxaparin activity losses of up to 65%. Fast freezing 
with slow thawing resulted in preservation of more than 98% of the initial AFXa 
activity even after 5 freeze/thaw cycles. Slow freezing with rapid thawing resulted in 
negligible loss of AFXa activity. 
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•Fast freezing/Rapid thawing 
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Figure 5.2 The effect on AFXa activity of: repetitive freezing (-196 °C) and thawing 
(room temperature) (A); increasing the duration held frozen at-196 °C before thawing 
(room temperature) (B) ; fast freezing (-196 °C) and thawing (room temperature) , fast freezing 
(-196 °C) and slow thawing (-80 °C, -26 °C, -12 °C, 0 °C over 36 hours), slow freezing 
(-12 °C, -26 °C, -80 °C, -196 °C over48 hours) with rapid thawing (room temperature) (C) 
(n=6, error bars represent ± SO). 
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It is recommended by the manufacturers that enoxaparin solution be stored 
below 25 °C. It is obvious from the results of this study that the freezing and 
subsequent thawing of enoxaparin solution can reduce its AFXa activity. The degree 
of activity loss was shown to be dependent on two factors, the freezing rate and the 
thawing rate of enoxaparin. Although freezing at lower temperatures appeared to 
increase the amount of AFXa activity lost, this was probably due to the greater rate of 
freezing rather than the exposure to lower temperatures, per se, since the gradual 
cooling of a sample to -196 °C, after freezing slowly at -12 °C, resulted in negligible 
loss of activity. Additionally, the length of low temperature storage time did not 
appear to have an effect on the degree of activity loss, over the time interval of the 
study. 
5.4.2 Chemical changes in frozen/thawed enoxaparin solution 
Results of analyses of free sulfate, free amino groups and reducing sugars 
present in unfrozen and liquid nitrogen frozen/thawed enoxaparin samples are 
presented in Table 5.1. A Student t-test showed no differences in the concentration of 
each analyte between frozen/thawed samples and corresponding controls. Therefore 
enoxaparin did not lose its anticoagulant activity by elimination of N-sulfo or 0-sulfo 
groups [6,15,108,109] which, in the case of N-sulfo groups would give rise to free 
amino groups [97]. Secondly, fragmentation of pol ysaccharide chains leading to 
generation of new non-reducing and reducing ends also was not responsible for 
changes in AFXa activity. Changes in the reducing capacity and associated changes in 
AFXa activity due to modification of the 1,6-anhydro groups can also be discounted. 
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Table 5.1 Determination of free sulfate groups, free amino groups and reducing sugars in 
unfrozen and frozen/thawed enoxaparin solution. Samples were analysed in triplicate with 
mean and relative standard deviation (% RSD, n=3) represented. 
Enoxaparin sample Free sulfate groups Free amino groups Reducing ends 
(mm oles/I) (mm oles/I) (mm oles/I) 
Mean %RSD Mean %RSD Mean %RSD 
Unfrozen 0.0181 1.52 0.011 3.6 0.019 5.9 
Frozen/thawed 0.0189 1.75 0.013 5.7 0.022 6.9 
5.4.3. SEM analysis of frozen enoxaparin solution 
The cryo SEM images of quench-frozen enoxaparin solution and water are 
presented in Figure 5.3. The image of frozen water (Figure 5.3A) shows the formation 
of ice crystals with clearly defined margins between the crystals. By comparison there 
are no obvious ice crystals or crystal margins evident in the images of enoxaparin 
solution quench-frozen on stubs cooled to -196 °C (Figure 5.3B). It was hypothesized 
that since ice crystal formation in polysaccharide solutions has been shown to be 
dependent on freezing temperatures [144], the observed decrease in AFXa activity of 
frozen enoxaparin may have been related to differences in ice crystal formation. The 
observations from the SEM study suggested that ice crystal formation was not 
responsible for the observed decreases in AFXa activity, since no ice crystals were 
visible in the frozen enoxaparin solution. This observation led to the investigation of 
the frozen glassy state transition (Tg) of enoxaparin solution. 
85 
Chapter 5 
B 
Figure 5.3 The SEM images of water (A) and enoxaparin solution (B) frozen on SEM stubs 
precooled in liquid nitrogen at -196 °C. 
5.4.4 Investigation of Tg of enoxaparin solution 
The DSC thermograms of enoxaparin solution are presented in Figure 5.4. The 
thermograms show heat flow during freezing at two different cooling rates, but not of 
the quench-frozen solution, and during thawing of three samples. These freezing rates 
were selected to understand the possible mechanism behind the observed differences 
in the activity loss under different freezing and thawing conditions (Figure 5.3C). The 
thawing thermograms through the Tg are presented in Figure 5.5. It can be seen from 
Figure 5.5 that Tg was similar regardless of the freezing rate. Calculated glass 
transition and melting parameters of quench-frozen enoxaparin solution are presented 
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in Table 5.2. Glass transition parameters were calculated using DSC software from 
the middle point within the range of temperature where the glass metastasis is almost 
done (Figure 5.5).The Tg occurred at -17 .8 ± 0.2 °C, which has not previously been 
reported for enoxaparin or other forms of heparin. The DSC results show that frozen 
enoxaparin solution exists in a glassy rather than a crystalline state, which is 
consistent with the SEM observations. Given that a similar glass transition was 
observed in enoxaparin solutions that were frozen at different rates and that the loss in 
AFXa activity was minimal with slow freezing, it appears that the loss in AFXa 
activity was not related to the glassy state transition. 
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Figure 5.4 DSC thermograms of enoxaparin solution (1 00 mg/ml) cooled at three different 
rates and then warmed at 10 °C/minute. 
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Table 5.2 Glass transition and melting parameters of quench-frozen enoxaparin solution from 
the DSC thermograms. All determinations are mean ± range (n=2). 
-1 .05 
c; -1 .10 
~ 
;: 
0 
u:: 
o; 
~ -1.15 
-1.20 
Glass transition parameters 
Onset temperature, T0 
Glass transition temperature, T9 
End temperature, Te 
Melting parameters 
Onset temperature, Tonset 
Peak temperature, Tpeak 
End temperature, Tend 
• - C 20oClmin 
0 --- Quench- DSC 
+- · 05oClmin 
oc 
-19.0±0.1 
-17.8 ± 0.2 
-17.7 ± 0.0 
oc 
0.4 ± 0.0 
7.4 ± 0.2 
26.3 ± 0.7 
-1.25+- ---~-~--.---~---.---~---~-."--'--i 
-30 -25 -20 -15 -10 -5 
ExoUp Temperature (0 C) UnivErsal V2.3C TA Instruments 
Figure 5.5 The DSC thermogram during warming of enoxaparin solution (100 mg/ml) showing 
the glassy state transition between -20 °C and -15 °C, for enoxaparin solutions frozen at three 
different rates. 
5.4.5 Role of cryoprotectants 
The effects of different concentrations of DMSO and 1,2-PD on the loss of 
AFXa activity of enoxaparin solution (100 mg/ml) frozen in liquid nitrogen and 
thawed at room temperature are shown in Figure 5.6. 1,2-PD and DMSO had 
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markedly different effects on the AFXa activity. 1,2-PD was ineffective in preventing 
AFXa activity loss when its concentration was 0.04% or less. A concentration of 
5% 1,2-PD still resulted in loss of 20% of the original AFXa activity. DMSO was 
more effective than 1,2-PD. It prevented the loss of AFXa activity at all 
concentrations tested, down to 0.008% v/v. These observations suggested that the 
action of DMSO, in preventing the loss of AFXa activity, is not related solely to its 
ability to inhibit the formation of ice crystals. Although it is used routinely as a 
cryoprotectant [145-148], the mechanisms by which DMSO acts as such are not well 
understood [149]. DMSO was reported to act as a disaggregating agent towards 
various starches [150] and was shown to be adsorbed on to the polysaccharide chain 
of aeromonas gum and prevent its aggregation [151]. 
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Figure 5.6 The effect of cryoprotectants at different concentrations on the loss of AFXa 
activity of enoxaparin solution (100 mg/ml) following freezing in liquid nitrogen and thawing at 
room temperature, (n=9, error bars represent± SO). 
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5.4.6 Influence of dilution prior freezing on the loss of AFXa activity 
The use of deionised water for the dilution of various LMWHs has been 
reported. [ 152-153]. The use of deionised water for the dilution of LMWH prior to the 
activity analysis is also recommended by the chromogenic assay kit manufacturer. 
Dager et al has reported no difference in the activity measurement of enoxaparin 
when it was diluted with water or 0.9% sodium chloride solution [152] . The loss in 
AFXa activity of diluted enoxaparin after freezing in liquid nitrogen and thawing at 
room temperature is shown in Figure 5.7. When enoxaparin was diluted with water, 
the loss of AFXa activity decreased after freezing with increased dilution. Loss in 
AFXa activity was around 66% when 100 mg/ml enoxaparin was frozen at -196°C. 
When it was diluted with water by a factor of two, the loss in activity was 45%. Ten-
fold dilution resulted in loss of only 4% of the original activity. Polysaccharides have 
a strong tendency to undergo aggregation with increased concentration and vice versa 
[ 154-156]. The observed reduced loss in AFXa activity with increased dilution 
supports the hypothesis that freezing- and thawing-induced aggregation of enoxaparin 
solution may be responsible for losses in AFXa activity. 
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Figure 5.7 The effect of dilution with water on the loss of AFXa activity of enoxaparin stock 
solution (100 mg/ml) following rapid freezing in liquid nitrogen and thawing at room 
temperature, (n=9, error bars represent± SO). 
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5.4.7 Effect of sonication on AFXa activity with different concentration of DMSO 
The AFXa activity of enoxaparin solution (100 mg/ml) remaining after 
freezing in liquid nitrogen followed by thawing at room temperature and the effects of 
sonication in the presence of different concentrations of DMSO on AFXa activity loss 
are presented in Fig. 5.8. Enoxaparin solution lost more than 45% of its initial AFXa 
activity after freezing and thawing. Addition of DMSO after freeze/thaw made no 
difference to the loss in AFXa activity when sonication was not employed. 
Comparison of the results from the sonicated samples by ANOV A revealed a 
significant main effect of DMSO concentration on AFXa activity [F(2,21)=184.2, 
p=<0.01]. Fisher's PLSD post-hoe tests revealed differences between AFXa activities 
in solutions with DMSO concentrations of 0% and 0.1 % (p<0.01), 0% and 
1 % (p<0.01), and 0.1%and1 % (p<0.01). The recovery of lost AFXa activity with the 
addition of 1 % DMSO and following sonication was 82% of the control 
(no sonication) activity loss. Sonication as a disaggregation treatment for many 
polysaccharides has been reported [157,158]. Geresh et al found sonication to be a 
successful means of disaggregating algal sulfated polysaccharide solutions [157]. 
Akiyoshi and co-workers found sonication to be more effective as a disaggregation 
treatment for a pullulan derivative in the presence of DMSO [158]. The current 
sonication study demonstrated that the loss in the AFXa activity after freezing and 
thawing can be partially restored with sonication and that sonication more effectively 
restores AFXa activity in the presence of 1 % DMSO. The results are consistent with 
freeze/thaw-induced aggregation of enoxaparin resulting in loss of its AFXa activity. 
Presumably this loss in activity is due to the reduced availability of active 
antithrombin binding sites since many of these sites would be hindered within the 
bulk of the aggregate, and there would also be steric effects from the aggregate bulk. 
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Figure 5.8 The effect of sonication on the AFXa activity of enoxaparin solution after 5 rapid 
(-196 °C) freeze/thaw cycles. DMSO was added to some solutions just prior to sonication. 
(n=15, error bars represent± SD). 
5.4.8 HP-SEC analysis 
The HPSEC chromatograms of an unfrozen sample of enoxaparin solution, 
samples frozen at -196 °C and thawed at room temperature with sonication (in the 
presence or absence of 1 % DMSO) or without sonication are given in Figure 5.9. The 
chromatogram of unfrozen enoxaparin solution (control, A) showed six distinct peaks 
that eluted over 10 minutes. The frozen and thawed enoxaparin sample (B) showed a 
marked reduction in the areas of peaks 3, 4 and 5 which are lower mass fragments, 
and there was a corresponding large increase in the areas of peaks 1 and 2 
corresponding to higher mass fragments. Samples sonicated in the absence of DMSO 
(C) showed an increase in the peak areas of lower molecular weight constituents with 
little change in the areas of the early eluted peaks. The chromatogram of enoxaparin 
sample sonicated in the presence of 1 % DMSO after freeze/thaw treatment (D) was 
similar to that of the unfrozen sample. 
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Figure 5.9 HP SEC chromatograms of enoxaparin solution (100 mg/ml) that was untreated (A), 
frozen rapid ly (-196 °C) and thawed (room temperature) (B), frozen and thawed as for B then 
sonicated either without (C) or with 1 % DMSO (D) (n=3). Peaks have been numbered to allow 
easy reference in the discussion. 
HP-SEC is the widely used analytical technique to study the aggregation 
behavior of polysaccharides. HP-SEC separation of polysaccharides is size dependent, 
in which larger fragments elute earlier than the smaller ones. The early elution of 
aggregated polysaccharide molecules has been reported [157,158]. The HP-SEC 
analysis of enoxaparin solution showed the presence of high mass fractions, consistent 
with polysaccharide aggregates, after freezing and thawing. After sonication of 
freeze/thawed enoxaparin in the presence of 1 % DMSO, the peak area of higher mass 
fragments returned to the control levels and there was a parallel increase in the peak 
area of lower mass fragments, consistent with disaggregation. This change also 
resulted in a corresponding increase in the AFXa activity (Figure 5.8). 
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It is known that polysaccharides are aggregated in aqueous solution on 
account of inter- or intra-molecular hydrogen bonding resulting from hydroxyl groups 
[124]. Dilution or addition of DMSO prior to freezing of enoxaparin decreased the 
activity loss. Xu and co-workers have reported that the driving force for the 
aggregation of polysaccharides increased with increasing the concentration at lower 
temperatures [159], consistent with the result obtained in this study. Dilution 
increases the distance between different constituents of enoxaparin and decreases the 
inter- and intra-molecular hydrogen bonding and hence aggregation. It has been 
shown that DMSO forms coating on the polysaccharide chains of aeromonas gum and 
prevents contact of the oligosaccharide chains and hence decreases the number of 
aggregates [151]. Based on the results obtained in this study it is suggested that 
DMSO has prevented aggregation by disturbing inter- or intra-molecular hydrogen 
bonding at lower temperatures. 
HP-SEC is the established standard in phi:µmaceutical industries for the 
detection and quantification of soluble aggregates [141]. HP-SEC is considered as a 
sensitive, efficient and reliable technique for the determination of aggregates [113-
114, 117]. The main reason behind the use of HP-SEC in this study was its easy 
accessibility in our laboratory. Ultracentrifugation requires expensive specialised 
instrument and the procedure for aggregate determination is time consuming [136]. 
This technique was not available for this study. Another possible alternative was the 
combination of HP-SEC - MALLS. The superiority of a light scattering technique is 
that the analysis is based on the molecular weight and concentration of solute. For a 
low molecular weight analyte (MW< 6000 Da) this method requires a higher 
concentration of solute to be injected on to the column compared with UV detection 
[136]. Injection of more than 1 mg/ml of enoxaparin (MW 4500 Da) in the HP-SEC 
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column had an adverse affect on the chromatography, with a decrease in the number 
of peaks detected. Column overload could potentially have prevented the applicability 
of this light scattering technique. Quasi-elastic laser scattering was not used in this 
study because of its well known drawback of low resolution. Unlike HPSEC, it is not 
able to resolve two constituents unless they differ in molecular mass by factor 8 [139]. 
Therefore it is considered as a poor technique for studying low mass molecules such 
as enoxaparin. A search of the literature did not show the use of MS for the analysis 
of intact LMWHs, therefore restricting its use in our study. 
Recommended storage conditions for heparin formulations are not 
unambiguous. Storage recommendations given on the packaging of heparin sodium 
formulations from different manufacturers differ from each other [ 113]. It is generally 
understood that a particular formulation should be stored according to the 
manufacturer's instructions. The label for enoxaparin (Clexane) states "store below 
25 °C" whereas, the EP-LMWHS (also prepared by P-eliminative cleavage) 
instructions state "keep at 4 °C and do not store at lower temperatures to avoid 
deterioration of the material". The label for dalteparin (Fragmin) states "store below 
30 °C and do not freeze". It is evident from this study that freezing adversely affects 
AFXa activity and that enoxaparin should not be frozen. Based on the results obtained 
in this study, it is recommended that the storage recommendations for enoxaparin 
should state that the preparation should not be frozen. 
5.5 CONCLUSION 
This study showed that the effect of freezing and thawing on the AFXa 
activity of enoxaparin solution is significant. Enoxaparin lost 64% of its initial AFXa 
activity after freezing at -196 °C and thawing at room temperature. The loss in 
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activity was even higher with an increase in the number of freeze/thaw cycles. The 
decrease in AFXa activity was not seen when enoxaparin solution was either frozen or 
thawed slowly. The frozen enoxaparin solution exists in a glassy state having a Tg at 
-17 .8 °C. The freeze/thaw effect on the AFXa activity of enoxaparin solution can be 
reduced by dilution with water or addition of DMSO prior to freezing. Aggregation 
was found to be the main cause of the lost AFXa activity after freeze/thaw treatment. 
Aggregation was found to be reversible by sonication in the presence of 1 % DMSO. 
Insight into the mechanisms by which enoxaparin lost AFXa activity after freeze/thaw 
treatment and different ways of preventing or recovering the lost activity may 
potentially give rise to new methods for the long-term storage of concentrated or 
diluted enoxaparin solutions. 
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CHAPTER6 
Stability Enhancement of Diluted Enoxaparin at Paediatric 
Dosage Levels 
6.1 SUMMARY 
Diluted enoxaparin is used for the long-term treatment of paediatric patients. The 
stability of diluted enoxaparin over extended periods has not been demonstrated. Diluted 
enoxaparin prepared extemporaneously has a shelf life of only 24 hours. This has resulted in 
the requirement for frequent fresh preparation of diluted enoxaparin for the long-term 
treatment of paediatric patients. The objective of the study was to find a method to store 
diluted enoxaparin for 31 days without losing significant AFXa activity. Commercially-prepared 
undiluted enoxaparin (100 mg/ml) or enoxaparin diluted with sterile water or sterile 4% 
glucose (to 20 mg/ml) was aseptically transferred into plastic tuberculin syringes or glass 
vials. Samples were kept at 4 °C, -12 °C or -80 °C for up to 31 days. The AFXa activity of 
stored solutions was determined after 0, 7, 14 and 31 days. The AFXa activity of the diluted 
samples was compared with the AFXa activity of undiluted enoxaparin solution stored for the 
same time periods at 4 °C. HP-SEC was used to examine the changes to the diluted 
enoxaparin solutions after storage. Enoxaparin diluted with 4% glucose retained greater than 
99% of its initial AFXa activity at 4 °C after 31 days. Enoxaparin diluted with water lost almost 
10% of its original activity after 31 days at 4 °C and lost more than 10% of its activity after 
freezing at -12 °C or -80 °C. Storage in glass or plastic containers made no difference to the 
loss in the activity. Dilution of enoxaparin with 4% glucose and storage at 4 °C preserved 
more than 99% of the initial AFXa activity after 31 days, compared with a loss of 10% of the 
initial activity in the enoxaparin solution diluted with water and stored under the same 
conditions. Dilution with 4% glucose offers advantages for the preparation of stable paediatric 
doses of enoxaparin. 
6.2 INTRODUCTION 
Thrombotic incidents are not frequent in paediatric patients. However, these 
events can occur as secondary complications of heart diseases, prematurity, infections 
and cancer [160,161]. Many neonates receive prolonged intravenous infusions that 
require indwelling catheters. Patients with central venous infusion are at risk of 
catheter related thrombi [162-165]. Resolution of thrombi requires long-term LMWH 
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therapy [166,167]. LMWHs are the preferred anticoagulant agents, particularly in 
paediatric patients, over unfractionated heparin because of minimal monitoring 
requirements, more predictable dosage and fewer adverse effects. Among all the 
current existing LMWHs, enoxaparin has the majority of data supporting its paediatric 
use [162,168,169]. 
At present, the least concentrated commercial form of enoxaparin available is 
100 mg/ml. Paediatric enoxaparin doses are weight-based and the commercially 
available preparations cannot be used to measure the small doses required by infants. 
Therefore, prior dilution must be made for safe and effective use. The dose of 
enoxaparin to achieve adult therapeutic AFXa levels in paediatric patients has been 
assessed [ 170]. The initial treatment and prophylactic doses of enoxaparin for patients 
aged greater than 2 months were determined to be 1.0 mg/kg and 0.5 mg/kg 
respectively. Infants less than 2 months of age required a greater dose per kilogram 
because of their larger volume of distribution or decreased plasma concentrations of 
AT. Treatment and prophylactic doses for these patients were determined to be 
1.5 mg/kg and 0.75 mg/kg respectively. The use of diluted enoxaparin in the 
management and prophylaxis of thromoembolism in low-weight patients has been 
described [171]. Levin et al have described the advantages of using enoxaparin to 
support treatment at the patient's home [172]. 
The dilution of concentrated enoxaparin to a concentration of 20 mg/ml has 
been described, with an expiry time of 24 hours under refrigeration after its 
preparation [167]. For paediatric outpatients, a weight-based diluted dose of LMWH 
is required from the pharmacy or hospital every second day. Daily preparation 
involves high labour cost and possible drug wastage as well as necessitating frequent 
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visits to a pharmacy or hospital for the infant's carers. In some cases, the hospital 
pharmacy gives detailed instructions and teaching sessions to the parents about 
dilution procedures, stability and storage conditions of the drug. Hospitals provide a 
procedure information sheet designed as a take home reference for parents. However, 
dilution on a daily basis can cause considerable challenges to the pharmacy technician 
or patient's carers, such as accuracy in dilution, sterility, drug wastage and failure to 
double check [173]. 
A supply of commercially-prepared or repackaged sterile diluted enoxaparin 
solution would be convenient and potentially reduce the stress to parents or care 
givers of frequent visits to the pharmacy or hospital. For this approach to be 
practicable, preservation of the AFXa activity of the diluted preparations for the 
duration of outpatient use must be confirmed. 
Based on the aggregation findings in the Chapter 5, it was hypothesised that 
the loss in activity of enoxaparin (20 mg/mL) stored at 4 °C observed by Dager et al 
[152] was due to aggregation and could be prevented by the addition of an agent such 
as DMSO. DMSO is used as a cryoprotectant [145-148] and it also acts to prevent 
aggregation by altering the hydrogen bonding interactions between and within 
molecules [151]. However, because DMSO has the potential for necrotizing and 
inflammatory effects upon subcutaneous injection [174], we chose safe and easily 
available glucose (monosaccharide) as an alternative substance to use as a modifier. 
The physicochemical investigations into the stability of frozen enoxaparin led 
us to the study of the stability-enhancing effects of various additives. The aim of this 
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study was to demonstrate the enhanced stability of diluted enoxaparin over a 31 day 
period under different storage conditions. 
6.3 EXPERIMENTAL 
6.3.1 J.v.((l,/erials 
The sodium salt of enoxaparin (100 mg/ml) was purchased from Aventis 
Pharma (Sydney, NSW, Australia). Enoxaparin activity was measured using a 
chromogenic AFXa activity kit# 832 from American Diagnostica Inc. (Stamford, CT, 
USA). All spectrophotometric measurements were made with a Bio-Rad microplate 
reader Model-680 (Bio-Rad Laboratories, Hercules, CA, USA). All other chemicals 
were of reagent grade from Sigma Aldrich (Castle Hill, NSW, Australia). 
6.3.2 Prep(l,mtion (l,lld AFX(I, (l,Ctivity determin(l,tion of diluted enox(l,p(l,rin 
Triplicate solutions of diluted enoxaparin were prepared from commercially 
available enoxaparin injection (100 mg/ml) and preservative-free sterile water or 
sterile 4% glucose solution. Concentrated enoxaparin solution (100 mg/ml) was 
diluted using a sterile needle and sterile plastic syringes to obtain a final concentration 
of 20 mg/ml. Diluted enoxaparin solutions were aseptically transferred either into 
1 ml plastic tuberculin syringes or glass vials and stored at 4 °C, -12 °C or -80 °C for 
up to 31 days. Additionally, concentrated enoxaparin solution was drawn from its 
commercial syringes into 1 ml plastic syringes under sterile conditions and stored at 
the same temperatures and for the same durations as the diluted enoxaparin solutions. 
Aliquots were removed from solutions stored in plastic containers at 0, 7, 14 
and 31 days, whereas aliquots from solutions stored in glass containers were removed 
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after 31 days, to measure AFXa activity. The activity of enoxaparin was determined 
as described in section 2.3.2. A standard plot was generated on each test day by 
triplicate analysis of 5 different concentrations of enoxaparin (0.25, 0.125, 0.0625, 
0.0312 IU/ml). Two controls with known, but different concentrations (0.25 IU/ml 
and 0.0312 IU/ml) of enoxaparin were tested concurrently with the test samples on 
each week of analysis to confirm testing accuracy. At each time point concentrated or 
diluted enoxaparin samples from three separate plastic syringes were analysed in 
duplicate. 
6.3.3 Statistical analysis 
The AFXa activity of stored enoxaparin solutions at each time point was 
compared with baseline AFXa activity. Mean values for the AFXa activity between 
initial and subsequent days were analysed by analysis of variance (factorial design by 
three treatments: temperature, concentration and diluent) using SAS/STAT software. 
Differences between baseline and subsequent time periods, with p<0.05, were 
considered statistically significant. A clinically significant loss in the activity of a 
pharmaceutical drug is routinely defined as a loss of greater than 10% of the initial 
activity. 
6.3.4 HP-SEC analysis 
HP-SEC was performed, as described in section 4.3.5, on water- and 
4% glucose-diluted enoxaparin samples before and after storage at -12 °C for 31 days. 
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6.4 RESULTS AND DISCUSSION 
The remaining AFXa activities of diluted (20 mg/ml) and undiluted 
(100 mg/ml) enoxaparin samples after storage for 31 days at three different 
temperatures are presented in Table 6.1. The recommended temperature for storage of 
diluted enoxaparin is 4 cc. Enoxaparin diluted with water retained more than 98% of 
its initial AFXa activity after 7 days at 4 cc but lost 10% of AFXa activity after 31 
days. By comparison, enoxaparin diluted with 4% glucose stored at the same 
temperature, lost no activity after 31 days. 
Storage of frozen solution at-12 cc resulted in a 15.8% loss of AFXa activity 
in the concentrated enoxaparin solution after 31 days. By comparison, water-diluted 
enoxaparin also lost 12.4 % of its initial activity. However, 4% glucose-diluted 
enoxaparin solution did not lose a statistically significant amount of its AFXa activity. 
The freezing of concentrated or diluted (with water or 4% glucose) enoxaparin 
at -80 cc resulted in loss in AFXa activity after 7 days. Concentrated and 
water-diluted enoxaparin lost more than 18% of the initial AFXa activity after 31 days 
of storage. By comparison, enoxaparin diluted with 4% glucose solution preserved 
more than 90% of its AFXa activity. 
The AFXa activity remaining after repackaging of glucose-diluted enoxaparin 
solution in to glass vials at three different temperatures over 31 days are also shown in 
Table 6.1. Storage in glass, compared with plastic, containers made no difference to 
the loss in AFXa activity. 
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Table 6.1 Comparison of % AFXa activity remaining in enoxaparin sodium solutions diluted to 20 mg/ml with 4% glucose or water, or 
undiluted (100 mg/ml) after storage at 4 °C, -12 °C or -80 °C for 0, 7, 14 or 31 days. Samples were prepared in triplicate and analysed in 
duplicate. 
% AFXa activity remaining 
Plastic Glass 
Diluent Temperature (QC) DayO Day7 %RSD Day 14 %RSD Day31 %RSD Day 31 
Glucose 4.0 100.0 99.4 1.4 98.6 1.5 99.4 1.4 99.3 
4.0 100.0 98.1 1.8 93.7 
. . 
Water 3.2 90.0 2.4 
Undiluted 4.0 100.0 100.0 2.0 100.0 2.5 100.0 1.1 
Glucose -12.0 100.0 98.5 1.5 97.3 1.9 97.8 1.0 97.2 
-12.0 100.0 97.0 1.2 91.2 
. 
2.2 87.6 
. 
Water 3.5 
-12.0 100.0 95.1 
. 
88.4 
. . 
Undiluted 2.8 2.0 84.2 2.1 
Glucose -80.0 100.0 94.2 
. 
1.9 93.4 
. . . 
2.3 90.4 2.2 90.1 
100.0 89.1 
. 
85.2 
. . 
Water -80.0 3.0 2.6 81.8 2.6 
-80.0 100.0 80.4 
. 
79.3 
. . 
Undiluted 3.7 3.7 79.8 2.7 
p<0.05 compared with Day 0 
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The molecular distribution profiles of enoxaparin diluted with water or 4% 
glucose stored at -12 °C over 31 days are presented in Figure 6.1. HP-SEC resolved or 
partially resolved enoxaparin into six different regions. Both diluted enoxaparin 
samples gave an essentially identical HP-SEC profile prior to storage on Day 0. 
Interestingly the distribution profile of water-diluted enoxaparin differed from that for 
the glucose-diluted enoxaparin after storage at -12 °C for 31 days. HP-SEC of 
water-diluted enoxaparin showed a reduction in the peak areas of regions 3, 4, 5 and 6 
and an increase in peak area 2. The distribution profile of the 4% glucose-diluted 
enoxaparin sample was no different from that of the samples before storage. 
Dilution of enoxaparin with water resulted in a significant loss of AFXa 
activity after 31 days of storage at every experimental temperature. Undiluted 
enoxaparin lost an even greater percentage of its AFXa activity when stored as frozen 
solutions at -12 °C and -80 °C. It is clear from these results that the freezing of 
concentrated or water-diluted preparations of enoxaparin is not a suitable way to 
preserve AFXa activity. By comparison, enoxaparin diluted with 4% glucose 
maintained more than 99% of its original activity when stored for 31 days at 4 °C. 
When frozen at -12 °C, glucose-diluted enoxaparin lost only 2% of its AFXa activity 
after 31 days. 
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Figure 6.1 HP-SEC chromatograms of diluted enoxaparin at Day 0 (-), and 4% glucose 
diluted(-) and water diluted enoxaparin (-)stored at -12 °C for 31 days. 
These results show that glucose acts to prevent the storage-induced loss of 
AFXa activity of diluted enoxaparin when stored unfrozen or frozen at moderate 
temperatures. At a low freezing temperature (-80 °C) glucose gave some protection 
but did not prevent a significant loss in AFXa activity. Diluted enoxaparin for 
paediatric use could be safely stored in a domestic refrigerator at 4 °C without losing 
AFXa activity for at least 31 days, if diluted with 4% glucose, but not if diluted with 
water. In this study, the measured AFXa activity loss of the water-diluted enoxaparin 
stored at 4 °C (10%) for 31 days was consistent with the study conducted by Dager 
et al [152]. They reported a 9% loss in AFXa activity of water-diluted enoxaparin 
after 28 days at 4 °C. 
The effect of freezing on the AFXa activity of water-diluted and concentrated 
enoxaparin was dramatic. Evidence of aggregation can be seen in the HP-SEC 
chromatogram of water-diluted enoxaparin frozen at -12 °C. Aggregation resulted in 
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the loss of the peak areas of the lower mass fragments that eluted later from the size 
exclusion column. There was a corresponding increase in a higher mass fraction. The 
increase in this fraction and the corresponding loss of AFXa activity were shown to be 
reversible by sonication in Chapter 5. 
Few studies of monosaccharides as cryo-protectants have been reported. 
[110,144,175-181]. An alternative modifier considered was DMSO, but the relative 
safety and ready availability of 4% glucose solution in clinical pharmacies made this 
modifier the first choice. Two different mechanisms by which monosaccharides act as 
cryo-protectants have been reported. Firstly, these cryo-protective agents prevent the 
rapid ice crystal growth and stabilise food products [110,144]. However, SEM and 
DSC results suggested formation of a glassy state rather than crystalline state in 
frozen enoxaparin solution. Secondly, the formation of hydrogen bonding between 
sugar and protein molecules minimises the aggregation and stabilises them at lower 
temperature [ 17 5]. Aggregation of polysaccharides at lower temperature as a result of 
inter- and intra-molecular hydrogen bonding has been reported. Hydrogen bonding 
between glucose (36 mg/ml) and oligosaccharides (20 mg/ml) in the 4% glucose 
diluted enoxaparin solution (20 mg/ml) may have prevented inter- or intra-molecular 
oligosaccharide interaction that results in aggregation. The mechanism for 
aggregation of oligosaccharides and larger polysaccharides has not been extensively 
studied. The freezing behavior and aggregation of polysaccharide mixtures are 
complex processes and not well understood. 
A paediatric enoxaparin dosage, if diluted with 4% glucose solution, would 
contain 0.8 to 2.4 mg of glucose per kg body weight delivered subcutaneously. This 
delivery of 0.8-2.4 mg/kg of glucose compares with intravenous infusions containing 
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glucose for infants which deliver around 360 mg/kg/hour [182]. Typical ~ant blood 
glucose levels are around 76 mg/100 ml [182], so the subcutaneous delivery of 0.8-2.4 
mg/kg of glucose would have negligible effects on blood glucose levels. 
A supply of sterile 4% glucose-diluted enoxaparin for paediatric use would 
avoid the necessity for frequent preparation of paediatric dosages of enoxaparin 
resulting in numerous advantages for carers of paediatric patients. There would be 
savings in preparation cost, greater quality control (compared with home based 
dilution by non-health personnel) and less inconvenience to care givers. 
Various LMWHs are different in regard to their parent unfractionated heparin 
source, their chemistry, production processes and their safety and efficacy [183]. The 
demonstrated 31 day stability of 4% glucose-diluted enoxaparin cannot be presumed 
for other commercially available LMWHs. Further in vivo study of 4% glucose-
diluted enoxaparin solution delivered subcutaneously is needed in order to prove its 
safety in paediatric patients. 
6.5. CONCLUSION 
This study has shown that enoxaparin diluted with 4% glucose to a paediatric 
dosage concentration (20 mg/ml) can be successfully stored for a minimum of 31 days 
at 4 °C without significant loss of AFXa activity. Dilution with 4% glucose offers a 
potential method for the preparation of stable paediatric doses of enoxaparin. Further 
studies to determine the safety of glucose-diluted enoxaparin and its stability over a 
longer period of time are warranted. 
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CHAPTER7 
Investigation of the Effect of Heating on the Chemistry and 
Biological Activity of Enoxaparin 
7.1 SUMMARY 
The objective of this study was to investigate the effects of heating on the chemical 
and physical properties of enoxaparin and subsequent changes to its AFXa activity. 
Enoxaparin samples were heated at 70 °C for periods of up to 576 hours (24 days). 
Enoxaparin lost more than 25% of its initial AFXa activity after 8 hours and then regained 
more than 75% of the lost activity over the next 4 hours. Activity then decreased slowly, with a 
further 14% loss of the initial activity after 576 hours. The initial loss in activity correlated with 
desulfation, particularly N-desulfation, which was demonstrated by analysis of free sulfate and 
free amino groups. Analysis of reducing capacity demonstrated that fragmentation of 
oligosaccharides occurred at elevated temperature. CE analysis supported these findings. 
Enoxaparin was fractionated by HP-SEC and individual fractions were analysed. Early eluting 
fractions, containing aggregated oligosaccharides, increased in concentration following 
heating. There was a loss of up to 65% of sulfate from some fractions containing primarily 
hexa- and octa-saccharides after 8 hours corresponding to decreased AFXa activity. 
Fractions corresponding to low mass oligosaccharides increased in concentration and had 
increased AFXa activity between 8 and 12 hours. Ion-interaction RP-HPLC analysis 
supported these findings. Deca-, dodeca- and tetradeca-saccharides were resistant to 
chemical degradation when heated. Three processes, desulfation, aggregation and 
fragmentation occur during the heating of enoxaparin that result in the initial rapid loss, 
recovery and subsequent gradual loss of AFXa activity. These processes do not affect all 
fractions of enoxaparin to the same extent. 
7.2 INTRODUCTION 
Biological activity and chemical studies of pharmaceutical formulations 
exposed to elevated temperatures are commonly carried out to determine the stability 
of a drug and possible mechanisms by which the drug undergoes degradation and loss 
its activity. An accelerated stability study of heparin under acidic and basic conditions 
showed that the decomposition of heparin involved the endolytic hydrolysis of 
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glycosidic linkages and desulfation [97]. Stability studies of enoxaparin (10 mg/ml) 
have shown that more than 15% of its initial AFXa activity was lost after 10 days at 
22 °C and 10% of the initial AFXa activity was lost from diluted enoxaparin 
(20 mg/ml) at 4 °C after 30 days [173,184]. However, these studies did not expose 
enoxaparin to high thermal stress and did not investigate the mechanism(s) 
responsible for the loss in AFXa activity. Despite its routine and extensive use, 
detailed stability studies of enoxaparin have not been reported and the mechanism(s) 
by which it loses its AFXa activity are not elucidated. A preliminary study of 
enoxaparin stability at elevated temperatures showed unusual patterns of change in 
the AFXa activity, with an initial rapid decrease in activity followed by an increase in 
activity, then a gradual decrease [185]. By developing an understanding of the 
chemical changes that occurred during heat-induced degradation of enoxaparin 
solution, in combination with measurement of AFXa activity, it was postulated that it 
may be possible to increase the understanding of the chemistry, activity and stability 
of various constituents of enoxaparin. 
The purpose of the study was to investigate the effects of heating on the AFXa 
activity of enoxaparin solution, to examine heating induced chemical and physical 
changes to enoxaparin, and to determine the mechanism(s) by which enoxaparin 
solution loses its AFXa activity at elevated temperature. 
7.3 EXPERIMENTAL 
7.3.1 Materials 
The sodium salt of enoxaparin (100 mg/ml) was purchased from Aventis 
Pharma (Sydney, NSW, Australia) and used as supplied at pH 7.0. The EP-LMWHS 
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was from Pharmacopee Europeenne (Strasbourg, France). The AFXa activity kit 
# 832 was from American Diagnostica (Stamford, CT, USA). The bicinchoninic acid 
(BCA) assay kit to determine reducing capacity and fluoraldehyde assay reagent to 
measure free amino groups were from Pierce (Rockford, IL, USA). N-acetyl-D-
glucosamine, ammonium acetate, sodium sulfate, sodium hydroxide, hydrochloric 
acid, acetic acid, orthophosphoric acid, nitric acid, hydrogen peroxide, glycine, azure 
A, acridine orange, TBAH and acetonitrile were of analytical grade and all other 
chemicals were of reagent grade from Sigma Aldrich (Castle Hill, NSW, Australia). 
Microtitre plates were flat-bottomed polystyrene plates from Coming (Coming, NY, 
USA). Ultrafiltration membranes with 1 OOO Da cutoff were from Millipore (North 
Ryde, NSW, Australia). Electrophoresis was performed on a Criterion® precast gel 
(10% Tris-HCl) using a Bio-Rad power/Pac 200® power supply and Criterion® 
electrophoresis cell from Bio-Rad laboratories with silver staining performed using 
the Silver Stains Plus Kit®, all from Bio-Rad laboratories (Hercules, CA, USA). 
7.3.2 Analysis of AFXa Activity 
The activity of enoxaparin solution was determined using the 
ACTICHROME® AFXa chromogenic assay kit as described in section 2.3.2. The 
AFXa activity of each enoxaparin sample was determined in triplicate. 
7.3.3 Sample preparation for sulfate determination 
Total sulfate content of untreated enoxaparin solution (3 mg in 30 µl) and 
enoxaparin fractions (100 µl of each HP-SEC fraction) was determined after acid 
hydrolysis with a mixture of nitric acid and hydrogen peroxide as described 
previously [186]. Enoxaparin samples were mixed with nitric acid (1mlor200 µl) in 
a capped glass test tube or a capped 1.4 ml polyethylene centrifuge tube respectively. 
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Samples were heated at 80 °C overnight in a temperature controlled heating block. 
Hydrogen peroxide (0.2 ml or 50 µl respectively) was then added and the temperature 
was increased to 110 °C for 6 hours. Solutions were then neutralised using an 
experimentally determined volume of 1 M sodium hydroxide. The digested untreated 
enoxaparin was diluted with Milli-Q water to 5.0 ml in a volumetric flask and then 
250 µl of this solution was further diluted to 5.0 ml. The HP-SEC fraction samples 
were freeze dried and dissolved in Milli-Q water (500 µl). Samples were injected into 
an IC system for sulfate analysis. Total sulfate determination of the digested untreated 
enoxaparin samples was also carried out using gravimetric and spectroscopic 
analyses. Determination of free sulfate in undigested enoxaparin was determined after 
ultrafiltration of diluted enoxaparin using a 1 OOO Da cutoff filter at 15 OOO rpm for 10 
minutes. 
7 .3.4 Gravimetric sulfate analysis 
Total sulfate content in the enoxaparin sample was determined by precipitation 
of sulphate ions in the acid digested solution as barium sulphate [186]. Enoxaparin 
solution was acid digested as described above and 10% w/v barium chloride was 
added. The suspension was allowed to settle for 2 hours and complete precipitation 
was tested by addition of barium chloride to the supernatant. The mixture was then 
filtered through ash-free filter paper and filtrate was placed in a previously weighed 
porcelain dish. The filtrate was then kept in a muffle furnace at 800 °C for an hour. 
7.3.5 Spectrophotometric sulfate analysis 
Spectrophotometric analysis for total sulfate determination was carried out 
using conditioning and precipitating reagents. The conditioning reagent was prepared 
as follows: hydrochloric acid (0.3 ml), 95% isopropyl alcohol (0.7 ml), sodium 
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chloride (0.5 grams) and glycerol (0.4 ml) were dissolved in deionised water (2.5 ml) 
and mixed well. The precipitating reagent was prepared by dissolving barium chloride 
crystals (225 mg) in deionised water (1 ml). The acid digested enoxaparin sample 
(170 µl) was transferred to a low volume microtitre plate. Conditioning reagent (20 
µl) and then barium chloride solution (10 µl) were added and the plate was kept aside 
for 10 minutes. After 10 minutes the plate was shaken for 3 minutes and spectroscopic 
readings were taken at 420 nm. Sulfate stock solution was prepared by dissolving 
anhydrous sodium sulfate (40 mg) in distilled water (10 ml) and serial dilution was 
performed to achieve standard sulfate concentrations. 
7.3.6 IC Analysis of sulfate 
Determination of sulfate content was carried out by IC analysis as described in 
section 5.3.7. 
7.3.7 Analysis of free amino groups 
The determination of free amino groups in enoxaparin samples was 
determined by a fluoraldehyde-based assay as described in section 5.3.8. 
7.3.8 Analysis of reducing capacity 
The reducing capacity of enoxaparin samples was determined by a reducing 
capacity assay as described in 5.3.9. 
7.3.9 CE analysis 
CB analysis of enoxaparin samples was performed as described in section 
3.3.2. with the use of a 70 cm fused silica capillary (50 µm i.d.) having a detection 
' 
window 8.5 cm from the distal end, phosphate electrolyte (pH 3.5; 50 mM), an 
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applied voltage of -30 kV, UV detection at 230 nm and sample injection at 20 mbar 
for 5 seconds. Adjustment of pH of enoxaprin solutions was carried out as described 
in section 3.3.2. 
7.3.10 PAGE analysis 
Unstressed and heat stressed enoxaparin samples were subjected to PAGE. 
The tank buffer solution was prepared by mixing glycine (2.2% w/v) with Tris base 
(4.5 grams) and pH was adjusted to 8.3 with 5 N hydrochloric acid. Sample buffer 
solution was prepared by mixing Tris base (1.5% w/v) with 5 ml of glycerol. 
Bromophenol blue was then added as an indicator to the above solution and the pH 
was adjusted to 6.8 with 5 N hydrochloric acid. Samples were diluted with deionised 
water to achieve concentrations of 10 ng/ml to 100 µg/ml. These samples were again 
diluted with an equal volume of sample buffer solution. Unstressed (5 ng/ml to 
50 µg/ml) and stressed (30 and 50 µg/ml) enoxaparin samples (10 µl) were identically 
loaded on to each lane of four different 12 lane gels. Electrophoresis was performed at 
a constant current of 40 mA. 
Electrophoresis of the first gel was performed by running it for 4 hours. 
Subsequent staining was performed with a solution containing acridine orange 
(10 mg), methanol (5 ml) and deionised water (95 ml) for 1 hour. This gel was fixed 
for 1 hour with an aqueous solution of methanol (40% v/v) and acetic acid (10% v/v). 
The stained and fixed gel was then destained by washing several times with deionised 
water. 
Electrophoresis of the second gel was performed by running the gel for 
2 hours. Subsequent staining was performed with a solution containing sodium 
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formate (0.34% w/v) and azure A (0.1 % w/v) at pH 3.5 for 1 hour. Following staining 
of the gel, destaining was performed with the use of a solution containing sodium 
acetate (0.08% w/v) at pH 5.0. 
Electrophoresis of the third gel was performed by running it for 2 hours and 
subsequent silver staining was performed using the Bio-Rad Silver Staining Plus Kit®. 
Silver staining was fixed with acetic acid solution (5% v/v) for 15 minutes with 
subsequent washing using deionised water for 30 minutes. 
Electrophoresis of the fourth gel was performed by running the gel for 30 
minutes. This gel was stained with azure A, destained, then silver stained as described 
above. 
7.3.11 HPLC 
HP-SEC was performed using a Shodex OHpak SB-802.5 HQ 8mm x 300 mm 
size exclusion column and Security Guard equipped with a GFC 2000 cartridge 
(Phenomenex, Sydney, NSW, Australia). The mobile phase was 0.3 M sodium or 0.3 
M ammonium acetate (pH adjusted to 5.0 with 0.1 M HCl). The analyses were 
performed with a 30 µl sample injection at a flow rate of 0.3 ml/minute. 
Ion-interaction RP-HPLC of enoxaparin sodium was performed on a 5 µm 
Varian Microsorb C1s column (150 x 4.6 mm) (Varian, Melbourne, VIC, Australia). 
The mobile phase consisted of acetonitrile (32%), water (68%), TBAH (15 mM) and 
ammonium acetate (50 mM) at pH 7.0. Diode array detection was carried out at 230 
nm. The analyses were performed with a 30 µl sample injection at a flow rate of 1.0 
ml/minute. 
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7.3.12 The effect of heat stress on AFXa activity 
Glass ampoules (lrnl) were flushed with nitrogen gas for 5 minutes after 
addition of 50 µl of enoxaparin solution (100 mg/ml) and were rapidly flame sealed. 
Sealed glass ampoules with corresponding controls were kept at 70 °C in an oven or 
at 4 °C in a standard laboratory refrigerator [97]. Duplicate samples were removed 
from the oven at 0, 2, 4, 8, 12, 24, 48, 96, 182, 288 and 576 hours and were kept at 4 
°C until analysis. All samples, with corresponding controls, were analysed for AFXa 
activity on the same day. Duplicate samples were analysed in triplicate. 
7.3.13 The effect of oxygen on the loss of AFXa activity following heat stress 
Glass vials (2 ml) containing 50 µl of enoxaparin solution (100 mg/ml) were 
sealed with a crimped aluminium cap containing a teflon lined septum. Enoxaparin 
solution was then bubbled with oxygen or high purity nitrogen for 15 minutes via an 
18 G x 1 Vi" (1.25 x 38 mm) needle inserted through the septum, with a second needle 
acting as an exhaust port. After removal of the needles, the septum was sealed with 
neutral cure silicone sealant. Further glass vials containing enoxaparin were allowed 
to stand uncapped on the bench for 30 minutes in order to equilibrate with room air. 
Glass vials, in triplicate, containing different concentrations of oxygen were kept in an 
oven at 70 °C for up to 24 hours and corresponding controls were kept at 4 °C. 
Samples were removed from the oven at 0, 2, 4, 8 and 12 hours and AFXa activity, 
with corresponding controls, was determined in triplicate. A paired t-test was 
performed to investigate any significant differences between AFXa activity of 
controls and samples containing different concentrations of oxygen, with p<0.05 
considered statistically significant. 
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7.3.14 Investigation of heat-induced chemical changes on enoxaparin 
Enoxaparin solution (50 µl, 100 mg/ml) in glass ampoules was heat stressed at 
70 °C for up to 576 hours as described above. Each sample was analysed for free 
sulfate concentration, free amino groups and reducing capacity. Duplicate samples 
were analysed in triplicate. Selected samples were investigated chromatographically 
by HP-SEC and ion-interaction RP-HPLC and electrophoretically by CE and PAGE. 
7.3.15 Fractionation of enoxaparin samples and investigation of chemical and 
chromatographic properties of the fractions 
Enoxaparin samples stressed at 70 °C for 0, 8 or 12 hours were fractionated by 
HP-SEC. For each sample 20 fractions were collected over the same elution period 
between 18 and 28 minutes. Fractions were reanalysed for the peak distribution 
confirmation by HP-SEC. All the fractions were analysed for AFXa activity and 
sulfate content. Fractions containing higher mass components, previously shown to 
contain aggregated polysaccharides, were subjected to sonication for 0, 5, 20, 60 or 
300 seconds, in the presence of 1 % DMSO, a demonstrated disaggregation treatment 
[123], as described in section 5.3.13. AFXa activity of these fractions was determined 
before and after the disaggregation treatment. A paired t-test was used to determine 
any significant differences between AFXa activity of controls and disaggregated 
samples, with p<0.05 considered statistically significant. 
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7.4 RESULTS AND DISCUSSION 
7.4.1 AFXa activity of enoxaparin after heating 
A plot of percentage of AFXa activity remaining as a function of time at 70 °C 
for up to 576 hours is shown in Figure 7.1. There was a rapid decline in the AFXa 
activity between 0 and 8 hours, with a maximum loss of 27% of the initial AFXa 
activity. AFXa activity then increased after 8 hours, with AFXa activity returning to a 
maximum of 94% of the initial activity after 12 hours. AF.Xa activity decreased after 
12 hours, with activity falling to 84% after 48 hours, but then decreasing only to 80% 
of control over the next 22 days. The oxidative instability of heparin has been 
reported and anti-oxidants have been added during various manufacturing stages of 
heparin to enhance stability [41]. It was hypothesised that the initial rapid decrease in 
AFXa activity may be due to oxygen dependent degradation, due to the presence of 
some oxygen in the ampoules containing enoxaparin. Oxygen may have been 
dissolved in the enoxaparin solution or may have entered the ampoule before it was 
sealed. When enoxaparin was heated in the presence or absence of different 
concentrations of oxygen there was no difference in the loss of AFXa activity as 
shown in Table 7 .1. These results demonstrated that the initial rapid decrease in the 
AFXa activity was not oxygen dependant. 
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Figure 7.1 Percentage of initial AFXa activity and sulfate content remaining m enoxaparin 
solution kept at 70 °C for up to 576 hours. 
Table 7.1 Determination of AFXa activity of enoxaparin solution stored at 70 °C in the 
presence or absence of different concentrations of oxygen for up to 12 hours. 
Oxygen concentration(%) Time (hours) AFXa activity remaining(%) 
0.0 0.0 100.0 
4.0 82.4 
8.0 73.3 
12.0 94.4 
20.0 0.0 100.0 
4.0 81.9 
8.0 73.7 
12.0 94.9 
100.0 0.0 100.0 
4.0 82.4 
8.0 72.1 
12.0 93.8 
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7 .4.2 Desulfation of enoxaparin 
Chromatograms of different concentrations of sulfate ions in standard sulfate 
solution determined by IC are presented in Figure 7.2. The calibration plot of sulfate 
concentration vs. peak area showed a linear range (r2=0.9987, estimated using 
correlation coefficient) between 0.5 and 20 µg/ml concentarion. 
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Figure 7.2 Calibration IC chromatograms of sulfate standards. IC separation was carried out 
by hydroxide eluent generation using Dionex EluGen II KOH cartridge from 1 mM to 15 mM 
over 15 minutes. A Dionex lonPac Column (AS11) was used with a mobile phase comprising 
water and KOH as a gradient. Detection was carried out under suppression mode with flow 
rate of 1 ml/minute and injection volume of 25 µI. 
Free sulfate in enoxaparin solution determined by IC after ultrafiltration was 
found to be equivalent to 0.46% w/w based on an enoxaparin concentration of 
100 mg/ml. Total bonded sulfate in enoxaparin solution after acid hydrolysis, and 
allowing for the free sulfate, determined by IC, gravimetric and spectroscopic 
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analyses was 38.8% (0.59 %RSD), 37.4% (4.3 %RSD) and 36.4% w/w (5.9% RSD) 
respectively. Results for total bonded sulfate of enoxaparin obtained by three different 
methods were similar and the lowest %RSD was obtained with IC method. These 
values are similar to the theoretical estimation of sulfate content of enoxaparin 
(41.0% w/w) based on 75% trisulfation of the heparin disaccharide repeating unit 
from porcine mucosa, an average of 1 N-acetyl group per parent heparin molecule and 
the presence of 1,6-anhydro groups on the reducing end of 20% of the enoxaparin 
molecules. An experimental value of 34.7% w/w was determined previously for a 
non-commercial LMWH sample [ 186]. 
The loss of sulfate from heated enoxaparin is presented in Figure 7 .1. 
Enoxaparin lost sulfate rapidly, with more than 12% of the bonded sulfate content lost 
after 8 hours at 70 °C. The rapid loss of sulfate was paralleled by a similarly rapid 
loss of AFXa activity. Between 8 and 576 hours of treatment enoxaparin lost only a 
further 2.6% of the initial bonded sulfate. Therefore, the increase in the AFXa activity 
of enoxaparin after 8 hours is not related to any change in sulfate levels. 
The key structural unit of heparin or LMWH that confers AFXa activity is a 
pentasaccharide sequence consisting of three D-glucosamine and two uronic acid 
residues. The AFXa activity has been shown to be dependant on N- and 0-sulfate 
groups of this pentasaccharide sequence [6,15,16]. Elimination of the sulfate groups 
results in a decrease in AFXa activity, but the elimination of the 3-0-sulfate group of 
the central D-glucosamine results in complete loss of AFXa activity. 
In naturally occurring mammalian polysaccharides, the amino groups are 
usually N-acetylated but heparin contains a majority of N-sufated groups [97]. 
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N-sulfate groups are more heat labile than N-acetyl groups [187] and the loss of 
N-sulfate groups gives rise to the formation of free amino groups. The concentration 
of free amino groups following the heating of enoxaparin was determined using a 
sensitive fluoraldehyde assay and the results are presented in Figure 7.3. 
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Figure 7.3 Increases in the concentrations of free sulfate, free amino groups and in the 
reducing capacity of enoxaparin solution kept at 70 °C for up to 576 hours. 
A rapid increase in free amino concentration was observed in enoxaparin samples 
heated for up to 8 hours at 70 °C followed by a small increase after this time. The 
increase in the free amino concentration concurrently with increased free sulfate 
concentration indicated that there was a rapid loss of N-sulfate groups from 
enoxaparin. The concentration of sulfate exceeded that of free amino groups, 
indicating that some loss of 0-sulfate also occurred. These findings suggest that the 
initial rapid loss of AFXa activity was due to desulfation of thermally labile 
constituents of enoxaparin. It is also evident that some sulfate sites or sulfates on 
121 
Chapter 7 
some enoxaparin constituents are thermally resistant to desulfation, since little 
desulfation occurred after 48 hours, and desulfation did not exceed 16% of the initial 
total bonded sulfate after 576 hours. 
7 .4.3 Determination of reducing capacity 
The reducing capacity of heat stressed samples was measured after different 
periods of heating. The control reducing capacity was 0.019 mmoles/l and the 
increases in reducing capacity brought about by heating are presented in Figure 7.3. 
A rapid increase in the reducing capacity of enoxaparin was observed throughout the 
first 24 hours of heating. No substantial further increase was observed in the time 
period from 24 hours to 576 hours. Polysaccharides, in general, have one reducing 
and one non-reducing end. The observed increase in reducing capacity of the heat 
treated samples could represent the formation of new reducing ends through the 
breakdown of glycosidic linkages, the formation of more reactive reducing ends 
through chemical modification of the reducing sugar residues or a combination of 
both processes. Enoxaparin, as a consequence of P-eliminative cleavage has 1,6-
anhydro groups on approximately 20% of its reducing ends. Hydrolysis of these 
groups could potentially result in increased reducing capacity. However, the 
magnitude of the increased reducing capacity was too great for it to be accounted for 
by chemical modification of existing reducing ends. These results indicated that 
fragmentation of oligosaccharides must have occurred. The cleavage of a long chain 
polysaccharide into two smaller chains can result in increased AFXa activity if these 
chains are sufficiently long to possess the pentasaccharide sequence that binds AT and 
is responsible for AFXa activity [188]. 
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7.4.4 CE analysis 
The changes in enoxaparin following exposure to elevated temperature were 
studied by CE analysis. Since most chemical changes were evident within 48 hours, 
CE analysis was performed using samples kept at 70 °C for 0, 8, 12, 24 and 48 hours. 
Different electropherograms were observed for each sample and are presented in 
Figure 7.4. A new peak with a migration time of 5.9 minutes was observed after 
8 hours. This was consistent with a desulfation product that would be expected to 
have an increased migration time due to it carrying less charge. CE analysis of 
polysaccharides in reverse polarity mode has shown that lower mass constituents 
migrate earlier than higher mass constituents [74]. Electropherograms of enoxaparin 
heated for 12, 24 and 48 hours showed a shift towards a greater proportion of more 
mobile constituents, with shorter migration times, with an increased number of peaks 
detected, consistent with more low mass constituents. This observation suggested the 
fragmentation of larger to smaller oligosaccharides following heating. These results 
are consistent with the reducing capacity results and demonstrated chemical changes 
and fragmentation in the samples treated at elevated temperature. 
7.4.5 PAGE analysis 
PAGE was used in attempt to determine the chemical changes in enoxaparin 
following heating at 70 °C for 0, 8 and 12 hours. PAGE has been successfully 
employed for the analysis of various oligosaccharides with the use of different 
cationic dyes for their visualization. In this study, staining of the gel was performed 
with acridine orange or azure A or by silver staining. No stained bands were visible 
when electrophoresis was performed for 4 or 2 hours following staining with acridine 
orange or azure A. Initially it was thought that these cationic dyes were not sensitive 
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Figure 7.4 Electropherograms of enoxaprin before and after stressing at 70 °C for up to 
48 hours. CE conditions are same as those described for Figure 3.2. 
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enough to visualise the separated bands. Therefore staining was performed by the 
more sensitive silver staining method. However, no band was visualised with silver 
staining, possibly because of the high mobility of the highly negatively charged 
constituents of enoxaparin. Subsequently a gel was run for 30 minutes in order to 
ensure retention of samples on the gel. This gel was stained with azure A followed by 
silver staining. A single band of enoxaparin (50 µg/ml) was clearly visible which 
moved at the same rate as the bromophenol blue indicator. This result suggested that 
staining method was successful but commercially available 10% Tris-HCl was not 
able to retain highly electrophoretic negatively charged constituents of enoxaparin. In 
a study carried out by Jandik and co-workers, PAGE was able to separate various 
degradation products of unfractionated heparin only after heating heparin at 100 cc 
for 1 OOO hours [97]. The conclusion from our study was that PAGE using 
commercial gels was unsuitable for the analysis of enoxaparin and its degradation 
products. 
7.4.6 HP-SEC analysis and fractionation of heat stressed enoxaparin 
Most chemical and AFXa activity changes were evident in the samples treated 
for up to 12 hours (Figure 7.1 and Figure 7.2). There fore HP-SEC was performed 
using samples kept at 70 cc for 0, 8 and 12 hours. The HP-SEC chromatograms of 
EP-LMWHS and enoxaparin treated for 0, 8 and 12 hours are presented in Figure 7.5. 
EP-LMWHS was resolved or partially resolved into 8 different peaks (labelled as a-h) 
by HP-SEC. The approximate molecular masses of oligosaccharides in the EP-
LMWHS HP-SEC peaks have previously been described [106]. These data were used 
to construct a partial standard plot covering the lower end of molecular mass (Figure 
7.6) as described previously [189]. 
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Figure 7.5 HP-SEC analysis of EP-LMWHS and enoxaparin. Enoxaparin solution was stored 
at 70 °C for up to 12 hours. Peaks b, c, d, e, f, g and h correspond to the tetradeca-, dodeca-, 
deca-, octa-, hexa-, tetra- and di-saccharides respectively. 
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Figure 7.6 The HP-SEC calibration plot generated using a value of 600 Da per disaccharide. 
Different HP-SEC chromatographic profiles were obtained for enoxaparin 
samples heated for 0, 8 and 12 hours, as shown in Figure 7.5. Unstressed enoxaparin 
was resolved or partially resolved into 7 different peaks (labelled as a-g) having the 
same retention times as the EP-LMWHS peaks. With the unstressed enoxaparin, peak 
a eluted at 19.3 minutes. The same peak was increased in area and height after 
8 hours and became even higher following 12 hours of heating. Generation of an 
extra peak, i, was observed in the 12 hours treated sample at 24.0 minutes with a 
concomitant decrease in the area of peakf The approximate molecular masses 
corresponding to peaks c, d, e, f, i and g of enoxaparin were estimated as 3 670, 
3 070, 2 490, 1 960, 1 830 and 1 200 Da respectively. The molecular mass of peak i 
was determined from the standard plot. The other peaks were estimated by direct 
comparison with the identified peaks of EP-LMWHS which is also prepared by 
P-eliminative cleavage of parent heparin, resulting in oligosaccharides with masses 
similar, if not identical, to the oligosaccharides in enoxaparin. 
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Unstressed and stressed samples were fractionated by HP-SEC and 20 
different fractions of each sample, eluted in the span of 18 minutes to 28 minutes, 
were collected and reanalysed by HP-SEC for the peak distribution confirmation as 
described in section 4.4.5 and results are as shown in Figure 7.7. The AFXa activity 
of HP-SEC collected fractions is shown in Figure 7 .8. Fractions 1 to 4 and 16 to 20 of 
unstressed enoxaparin were found to be less active than the other fractions. Fractions 
11 to 13 showed the highest AFXa activity. After 8 or 12 hours of heating the AFXa 
activity of fraction 2 was higher compared to fraction 2 from the control sample. 
Higher AFXa activity of fraction 2 was consistent with increased peak area of peak a. 
Heating made no difference to the AFXa activity of fractions 4 to 10 compared with 
control. After heating for 8 hours there was a loss in the AFXa activity of fractions 
11 to 13 compared with control. Fraction 13 decreased in AFXa activity by 65%. 
Heating for 12 hours had the same effect on fractions 11 to 13 as heating for 8 hours. 
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Figure 7.7 HP-SEC analysis of selected HP-SEC collected fractions of enoxaparin sample 
kept at 70 °C for 12 hours. 
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Figure 7.8 AFXa activity of HP-SEC collected fractions of enoxaparin samples kept at 70 °C 
for 0 or 8 or 12 hours. 
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Figure 7.9 Sulfate contents of HP-SEC collected fractions of enoxaparin samples kept at 
70 °C for O or 8 or 12 hours. 
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After 12 hours of heating, fractions 14 and 15 showed 114% and 418% increases in 
activity, respectively, compared with activity after 8 hours, corresponding to 
respective increases of 15% and 65% over control values. Increased AFXa activity of 
these fractions after 12 hours of heating was accompanied by the appearance of peak i 
in the HP-SEC chromatogram. 
The results of sulfate determination of HP-SEC fractions are presented in 
Figure 7.9. Heating resulted in the loss of sulfate only from fractions 11 to 15 
compared with control. These fractions also showed a parallel loss of AFXa activity 
after 8 hours of heating, but after 12 hours of heating fractions 14 and 15 
(corresponding to peak i) recovered some AFXa activity, compared with 8 hours. 
These results have confirmed that there are thermally labile enoxaparin constituents 
that are rapidly desulfated and are responsible for the early rapid loss in the AFXa 
activity. Other constituents (fractions 4 to 10, corresponding to tetradeca-, dodeca-
and deca-saccharides) are resistant to thermal desulfation and retained their AFXa 
activity. Fraction 13, corresponding to hexasaccharides, was the most thermally 
vulnerable fraction. It lost 65% of its initial AFXa activity and 60% sulfate loss was 
observed after 8 hours of heating at 70 °C. 
Samples showed the most obvious chemical and biological changes following 
heating were selected for the ion-interaction RP-HPLC analysis. The ion-interaction 
RP-HPLC chromatograms of thermally stressed and unstressed enoxaparin samples 
are presented in Figure 7.10. Ion-interaction RP-HPLC analysis of the enoxaparin 
HP-SEC fractions allowed the assignment of ion-interaction RP-HPLC peaks to the 
equivalent HP-SEC peaks (c-g and i) as shown in Figure 7.5. No major 
chromatographic differences in the later eluted peaks corresponding to the HP-SEC 
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Figure 7.10 Ion-interaction RP-HPLC analysis of enoxaparin solutions kept at 70 °C for 0, 8 or 12 hours. The Ion-interaction RP-HPLC 
methodology is described in experimental section. Peaks c, d, e, f, g correspond to tetradeca- (3 670 Da), dodeca- (3 070 Da), 
deca- (2 490 Da), octa- (1 960 Da), hexa-saccharides (1 830 Da) respectively. 
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peaks c, d and e following thermal stress at 70 °C for 8 or 12 hours compared with 
control sample were observed. This observation is consistent with the HP-SEC 
results. 
Different chromatographic profiles of thermally stressed and unstressed 
samples corresponding to HP-SEC peaks f, g and i were obtained as shown in 
Figure 7 .11. The total peak area of the peaks corresponding to HP-SEC peakf in the 
chromatogram (eluted between 11and19 minutes) decreased by 30% after heating 
for 12 hours. The peaks corresponding to HP-SEC peaks g and i (eluted between 3.5 
and 11 minutes) increased in total area by 340% after heating for 12 hours, compared 
with control. Some peaks were unchanged including those that eluted at 5.8 and 6.7 
minutes. The peak that eluted at 3.9 minutes decreased in area by 94% and peaks that 
eluted at 7.4, 7.9, 9.3, 9.9 and 10.1 minutes increased in area. Peaks in the sample 
heated for 12 hours that eluted at 7.4, 9.3 and 9.9 minutes were not detected in the 
control sample. These peaks represent new compounds resulting from chemical 
changes brought about by heating. The increase in the area of these peaks is 
comparable to the increased area and AFXa activity of fractions 14 and 15, 
corresponding to peak i, following 12 hours of heating. 
The AFXa activity of HP-SEC fraction 2 (corresponding to peak a) from 
samples heated for 0, 8 or 12 hours, was determined before and after sonication for 5, 
20, 60 and 300 seconds in the presence of 1 % DMSO, and the results are presented in 
Figure 7.12. 
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Figure 7.11 Ion-interaction RP-HPLC chromatogram of enoxaparin solution kept at 70 °C for 
O or 12 hours. 
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Figure 7.12 The AFXa activity of HP-SEC fraction 2 of enoxaparin samples kept for 0, 8 or 12 
hours at 70 °C, before and after sonication for up to 300 seconds in the presence of 
1 % DMSO. *Significant difference (P~ 0.05) from corresponding control (without sonication in 
the presence of 1 % DMSO). Error bars indicate mean ± S.D. 
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Figure 7.12 demonstrates three different things. Firstly, HP-SEC fraction 2 
after heating for 8 or 12 hours, had greater AFXa activity than the fraction 2 following 
heating for 0 hours. The aggregated fraction has a greater concentration of 
oligosaccharides and is expected to have higher AFXa activity. Fraction 2 after 
heating for 8 hours and 12 hours had 53% and 200% more AFXa activity than the 
control fraction (0 hours heated). HP-SEC analysis of unstressed and stressed 
enoxaparin showed a higher concentration of oligosaccharides in early eluted fraction 
2 following heating (Figure 7 .5). These results indicated aggregation of 
oligosaccharides following heating had occurred. 
Secondly, the recovery of AFXa activity of fraction 2 of heated enoxaparin 
samples was less when sonication time was greater than 20 seconds. The increase in 
the AFXa activity of fraction 2 of 12 hours heated sample was 15% less after 
sonication for 300 seconds compared with sonication for 20 seconds. Longer 
sonication time may have altered the structure of aggregated oligosaccharides as it has 
been reported that sonication of polysaccharide longer than 5 seconds causes 
degradation of aggregated constituents [123]. A short sonication period 
(5 or 20 seconds) was found to be the optimal time of sonication for the 
disaggregation of aggregated enoxaparin constituents. 
Thirdly, sonication in the presence of 1 % DMSO, a treatment shown to 
disaggregate polysaccharides [123], increased AFXa activity of 8 and 12 hours treated 
fractions but not of the control fraction (without sonication). Increases in the AFXa 
activity following sonication (20 seconds) in fraction 2 from enoxaparin samples 
heated for 8 and 12 hours were 77% and 88% compared with the control fraction. 
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These activities represent increases over the activity of untreated fraction 2 by 230% 
and 470% respectively. 
Decomposition studies of other LMWHs or parent heparin at elevated 
temperature would be required to determine whether the changes observed in this 
study of enoxaparin are unique to this LMWH or can be generalised to other LMWHs 
and unfractionated heparin. Further structural characterisation of thermally labile and 
thermally stable constituents and the degradation products detected in this study may 
allow the determination of the properties of these constituents. 
7.5 CONCLUSION 
This study identified three different processes that affect the AFXa activity of 
enoxaparin upon heating at 70 °C. A rapid loss of AFXa activity was primarily due to 
oxygen independent desulfation, particularly of N-sulfate groups and mostly 
involving hexa- and octa-saccharides. Desulfation occurred rapidly in the first 
8 hours. A further, comparatively slower loss of AFXa activity was due to 
aggregation. Increased AFXa activity after 8 hours was due to fragmentation, as 
determined by reducing capacity and supported by CE, HP-SEC and ion-interaction 
RP-HPLC analyses. Some fractions appeared to be resistant to chemical changes 
brought about by heating. A preparation containing these thermally stable constituents 
may provide a more stable LMWH formulation. 
135 
Chapter8 
CHAPTERS 
General Conclusion 
Commercially available LMWHs are depolymerised porcine mucosa! heparin 
preparations prepared by chemical or enzymatic digestion methods. Depolymerisation 
results in partial desulfation, reduced charge density and fewer AT binding sites. The 
depolymerisation procedure also creates LMW products about one third of the size of 
the standard heparin molecule. These LMW products are diverse in structure and 
functional properties as a result of different depolymerisation processes. 
Enoxaparin is the first of the new class of LMWH and is widely used as an 
anticoagulant agent. Despite its routine use, the possible mechanisms by which it 
undergoes degradation and loss of its activity have not been previously elucidated in 
the literature. This thesis has advanced the understanding of physicochemical 
properties of enoxaparin related to both biological activity and storage conditions. 
This has been achieved by improvements in the existing AFXa activity determination 
methodology and the development of improved novel analytical techniques with good 
resolution. 
European and British Pharmacopeial Commissions have adopted AFXa 
activity as a measure of biological activity of LMWHs. AFXa assays are based on the 
inhibition of a known amount of factor Xa, and are measured using a synthetic 
peptide substrate. Investigation of the changes that occur during the heating and 
freeze/thaw treatment of enoxaparin required a large number of AFXa activity 
analyses. The commercially available ACTICHROME® AFXa assay kit from 
American Diagnostica provides reliable and reproducible data for both heparin and 
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LMWHs. This AFXa assay kit method is difficult to perform manually, very 
expensive and extremely time consuming. The ACTICHROME® AFXa kit method 
was modified to a low-volume microtitre plate method. This method allowed 
simultaneous determination of 35 samples in less than 15 minutes compared with 
determination of 35 samples in 5 hours by the standard kit method. The low-volume 
microtitre plate method is not only faster and more sensitive but also economical as it 
uses fewer quantities (8 times) of reagents and samples (5 times) required for the 
AFXa activity analysis. This method facilitated multiple analyses of HP-SEC 
fractions, required to determine physicochemical properties of various 
oligosaccharides. This low-volume method allowed triplicate determination of AFXa 
activity, sulfate content and activity of disaggregated oligosaccharides of the same 
HP-SEC fraction. These multiple analyses would have not been possible with the 
ACTICHROME® AFXa kit method without preparative HP-SEC fraction collection. 
This method can also be successfully applied to the multiple analyses of RP-HPLC 
and CE fractions. 
Because of its high negative charge and structural complexity, enoxaparin and 
other LMWHs are extremely difficult to analyse by chromatographic methods. 
Several analytical techniques such as SAX and CE offer adequate resolution of 
various oligosaccharides, prepared by time consuming and laborious fractionation or 
depolymerisation of enoxaparin. However, analysis after digestion does not offer a 
convenient methodology for stability testing of enoxaparin. This thesis presents 
development and validation of two novel analytical methodologies, CE and 
ion-interaction RP-HPLC. The CE method has demonstrated a reduction in the run 
time and increased resolution compared to existing CE methods. It has the potential to 
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show structural differences within the two different batches of the same LMWH. The 
novel application of ion-interaction RP-HPLC method was demonstrated with both 
ELSD and diode array detection. This method showed improved resolution and base 
line separation of different LMWHs compared to any other existing analytical 
techniques. These methods have the potential to indicate stability and structural 
diversity between different LMWHs and were successfully applied to investigate 
chemical and physical properties of stressed and unstressed enoxaparin. 
The packaging labels for storage recommendations of three different LMWHs 
are different from each other. The label for enoxaparin bears "store below 25 °C". 
Recommended storage condition for EP-LMWHS is "store at 4 °C" whereas the 
packaging label for dalteparin states "do not freeze". Despite ambiguity about storage 
conditions, the effect of freezing and thawing on the activity of LMWHs has not been 
investigated. The freezing study presented here has demonstrated a severe effect of 
freeze/thaw treatment on the activity of enoxaparin. Based on this result, storage 
recommendations given on the packaging of enoxaparin formulation should state that 
the preparation should not be frozen. This study has established the different 
conditions under which AFXa activity is lost, retained and recovered. Detailed 
mechanistic study of enoxaparin showed aggregation as the main cause for the 
activity loss upon freezing and thawing. The effect of heating on the chemistry and 
AFXa activity of enoxaparin was comprehensively investigated. Development of 
novel and high resolution analytical techniques (CE and ion-interaction RP-HPLC) 
allowed exploration of the mechanisms involved for the rapid lost and subsequent 
increase in the AFXa activity of enoxaparin at elevated temperature. This study 
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determined three different processes, desulfation, fragmentation and aggregation 
which affect enoxaparin activity at elevated temperature. 
HP-SEC analysis has shown that upon freezing, larger oligosaccharides 
(deca-, dodeca- and tetradeca-saccharides) of enoxaparin undergo rapid aggregation 
compared to the smaller oligosaccharides (hexa- and octa-saccharides). IC, HP-SEC, 
CE, ion-interaction RP-HPLC and reducing capacity analyses showed that larger 
oligosaccharides (deca-, dodeca- and tetradeca-saccharides) are thermally stable 
constituents of enoxaparin. Smaller oligosaccharides of enoxaparin such as hexa- and 
octa-saccharides are clinically active but rapidly undergo fragmentation and 
desulfation. Smaller oligosaccharides are more stable at low temperatures than larger 
oligosaccharides. A LMWH preparation containing low mass fractions such as hexa 
and octa-saccharides can provide a formulation with greater stability at low 
temperatures. A LMWH preparation containing thermally stable fractions (larger 
oligosaccharides) offers a new formulation with greater shelf life. 
The stability of enoxaparin solution at paediatric dosage level is only 24 hours, 
which results in a requirement of fresh preparations. This study has shown that 
dilution of enoxaparin with 4% glucose at paediatric dosage levels can be successfully 
stored for a minimum of 31 days without loss in the AFXa activity. This stable 
formulation offers substantial advantages such as superior quality control, more 
convenience to care givers and lower cost of formulation. 
Analysis of various LMWHs by CE, ion-interaction RP-HPLC and HP-SEC 
showed that these anticoagulant agents are structurally and chemically different. 
Observed stability and physicochemical properties of various oligosaccharides of 
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enoxaparin at different storage conditions cannot be generalised to other LMWHs. 
Similar investigation of other LMWHs at freezing and accelerated temperatures 
would be desirable to determine whether these LMWHs undergo identical degradation 
processes or they behave differently depending on their unique structural characters. 
The research material presented here has shown the development and the 
novel application of CB and ion-interaction RP-HPLC analytical techniques for the 
stability analysis, chemical characterisation and batch-to-batch variation evaluation of 
intact LMWHs. Storage induced chemical and physical changes in enoxaparin under 
different conditions have been studied in detail. This study has investigated previously 
unknown processes which influence the AFXa activity of enoxaparin. There is now 
scope for the future formulation development of desirable LMWH constituents to 
increase shelf life, to improve therapeutic efficacy and to decrease adverse effects 
based on the novel analytical methods and extensive structural elucidation of 
enoxaparin presented in this thesis. 
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